Document:

Exhibit 10.45

             -------------------------------------------------------
                   Confidential treatment has been requested for
             portions of this exhibit. The copy filed herewith
             omits the information subject to the confidentiality
             request. Omissions are designated as [*]. A complete
             version of this exhibit has been filed separately with
             the Securities and Exchange Commission.
             -------------------------------------------------------

                             VAXGEN-CELLTRION, INC.

                          CONSULTING SERVICES AGREEMENT

      This Consulting Services Agreement (the "Agreement") is made and entered
into on the 7th day of June, 2002 (the "Effective Date") by and between
VaxGen-Celltrion, Inc., a California corporation, having an address at c/o
VaxGen, Inc., 1000 Marina Boulevard, Brisbane, CA 94005-1841 ("VCI"), and
VaxGen, Inc., a Delaware corporation, with a principal place of business at 1000
Marina Boulevard, Brisbane, CA 94005-1841 ("VaxGen"). (VCI and VaxGen are
sometimes referred to individually herein as a "Party" or collectively as the
"Parties.")

WHEREAS:

Vaxgen and VCI entered into a series of agreements on June 7, 2002, including a
license agreement, an executed copy of which is attached hereto as Schedule 1
("License Agreement"), all of which together set forth the terms for the
construction and operation of pilot manufacturing facilities for the production
of pharmaceutical products in South San Francisco, California;

VCI now desires to retain VaxGen as an independent contractor to perform the
Services (as defined and more fully described herein); and

VaxGen is willing to perform the Services on the terms and conditions set forth
herein.

NOW THEREFORE, in consideration of the mutual promises contained herein, the
Parties agree as follows:

                                    ARTICLE I

                                   DEFINITIONS

1.1 "Intellectual Property" shall mean all patents, inventions, developments,
discoveries, improvements, know-how, trade secrets, copyrightable material,
records, data, results, notes, computer files, records, trademarks, service
marks, trade names, names, marks, logos, brand names, designs, trademark and
service mark registrations,

<PAGE>

and any other intellectual property made, conceived, reduced to practice,
invented, or discovered by either Party or their employees, independent
contractors, consultants, agents, and representatives, prior to the Effective
Date or during the term of this Agreement.

1.2 "Licensed Knowhow" shall have the meaning ascribed to this term in the
License Agreement, which is attached hereto as Schedule 1 and incorporated
herein by reference.

1.3 "Licensed Patent Rights" shall have the meaning ascribed to this term in the
License Agreement attached as Schedule 1, which is incorporated herein by
reference.

1.4 "VaxGen Intellectual Property" shall mean all Intellectual Property (i)
owned or licensed by VaxGen prior to the Effective Date and (ii) made,
conceived, reduced to practice, invented, or discovered independently by VaxGen,
or its employees, independent contractors, consultants, agents, or
representatives, or licensed by VaxGen, during the term of this Agreement but
not in the course of providing Services hereunder. For the purpose of this
Agreement, the Licensed Knowhow, Licensed Patent Rights, and all improvements to
VaxGen Intellectual Property, conceived or developed independently by VaxGen,
its employees, independent contractors, consultants, agents, and
representatives, shall constitute VaxGen Intellectual Property.

1.5 "VCI Intellectual Property" shall mean all Intellectual Property (i) made,
conceived, reduced to practice, invented, or discovered independently by VCI,
and its employees, independent contractors, consultants, agents, and
representatives, expressly excluding VaxGen, prior to the Effective Date or
during the term of this Agreement and (ii) all Intellectual Property made,
conceived, reduced to practice, invented, or discovered by VaxGen, and its
employees, independent contractors, consultants, agents, and representatives
solely in the course of providing Services hereunder. For the purpose of this
Agreement, VCI Intellectual Property shall further include all improvements to
VCI Intellectual Property, which are developed or conceived during the term of
this Agreement independently by one or more employees, independent contractors,
consultants, agents, and other representatives of VCI and, solely in the course
of providing Services hereunder, by one or more employees, independent
contractors, consultants, agents, and other representatives of VaxGen..

1.6 "Work Product" shall mean all electronic and written records, files, and
samples of work produced during the term of this Agreement by VCI and, solely in
the course of providing Services hereunder, VaxGen, including, but not limited
to, reports, notes, data, sketches, drawings, media, and other representations
of such work.

                                   ARTICLE II

                            SERVICES AND COMPENSATION

2.1 Performance of Services. During the term of this Agreement, VaxGen shall
perform the following Services for VCI in a commercially reasonable manner and
in

                                       2
<PAGE>

accordance with the terms and conditions of this Agreement, and with any time
schedule, requirements, or other goals, which are agreed between VaxGen and VCI
pursuant to this Section 2.1:

      (a) the services set forth in the License Agreement and Sub-license
Agreement entered into between VaxGen and VCI,

      (b) the services requested by VCI in connection with the performance of
the License Agreement and Sub-license Agreement entered into between VaxGen and
VCI, and

      (c) other services reasonably requested by VCI.

2.2 Compensation. VCI shall pay to VaxGen compensation as set forth in this
Section 2.2 for the performance of the Services described in Sections 2.1(b) and
(c) above.

      (a) Payment of each VaxGen employee at a rate equal to the hourly rate of
such employee's annual salary, plus an additional overhead rate of [*], as set
forth in Schedule 2, and

      (b) Payment of independent contractor, consultant, agent, or other
representative of VaxGen hired by VaxGen on behalf of VCI in support of the
Services at a rate equal to the hourly rate of his or her contract rate.

The amount of compensation shall not be increased except upon the signed written
agreement of the Parties. The Parties agree that the compensation described in
this Section 2.2 is based solely on the performance of the Services described in
Section 2.1(b) and (c) above.

2.3 Reimbursement of Expenses. VCI shall reimburse VaxGen for all reasonable
out-of-pocket expenses, which are necessarily incurred on its behalf in the
performance of the Services by VaxGen, any employee, independent contractor,
consultant, agent, and/or other representative of VaxGen, including but not
limited to telephone, facsimile, shipping, postage, lodging, travel expenses,
provided that prior written approval shall be obtained before such travel
expenses are incurred. For any out-of-pocket expenses, with respect to which
VaxGen seeks reimbursement from VCI, VaxGen shall submit an itemized written
statement detailing such expenses, which shall be provided in a format
reasonably acceptable to VCI.

2.4 Payments and Capital Contributions by VaxGen. All compensation and
reimbursement payable to VaxGen pursuant to Sections 2.2 and 2.3 shall not be
deemed capital contributions by VaxGen as set forth in Article 5 of the VCI
Joint Venture Agreement. All payments pursuant to Sections 2.2 and 2.3 shall be
due and payable within sixty (60) days of the invoice date, and shall be
remitted to VaxGen at the following address: Attn: Carter A. Lee, VaxGen, Inc.,
1000 Marina Boulevard, Brisbane, CA 94005-1841, U.S.A. All sums, including
reimbursements, due payable under this

[*] Denotes confidential treatment requested. A complete version of this exhibit
has been filed separately with the Securities and Exchange Commission

                                       3
<PAGE>

Agreement shall exclude any value added goods and services, sales, or other tax,
duty, or levy, and shall be payable in U.S. Dollars.

2.5 Late Payments. On all amounts outstanding and payable, interest shall accrue
from the date such amounts are due and payable at the rate of one-half percent
(1/2%) per month on any amount required by this Agreement, commencing on the
date on which payment is due.

                                   ARTICLE III

                       OWNERSHIP OF INTELLECTUAL PROPERTY

3.1 Ownership of Intellectual Property and Work Product. All right, title, and
interest in VaxGen Intellectual Property shall be solely owned by VaxGen. All
right, title, and interest in VCI Intellectual Property and Work Product shall
be solely owned by VCI.

3.2 Assignment of Rights to Intellectual Property and Work Product. VaxGen
hereby certifies that each employee, independent contractor, consultant, agent,
and representative of VaxGen, having access to VaxGen Intellectual Property
and/or VCI Intellectual Property and Work Product, has signed an agreement with
VaxGen, which assigns and transfers to VaxGen all right, title, and interest in
any VCI Intellectual Property and Work Product conceived or developed during the
term of this Agreement. VCI hereby certifies that each employee, independent
contractor, consultant, agent, and representative of VCI, having access to the
VaxGen Intellectual Property and/or the VCI Intellectual Property and Work
Product, has signed an agreement with VCI, which assigns and transfers to VCI
all right, title, and interest in any VCI Intellectual Property and Work Product
conceived or developed during the term of this Agreement.

3.3 Improvements. VCI agrees that, if VaxGen, or any employee, independent
contractor, consultant, agent, and/or other representative of VaxGen, in the
course of performing the Services, and/or VCI, or any employee, independent
contractor, consultant, agent, and/or other representative of VCI, at any time,
incorporates any improvement, invention, development, concept, discovery, or
other proprietary information into VaxGen Intellectual Property, VaxGen shall
have a perpetual, irrevocable, worldwide, fully paid, royalty free,
non-exclusive right to practice, make, have made, sell, offer for sale, import,
modify, reproduce, display, and use, as applicable, such invention, improvement,
development, concept, discovery, or other proprietary information.

                                       4
<PAGE>

                                   ARTICLE IV

                                  INFRINGEMENT

      Sections 5.3 and 5.4 of the License Agreement attached hereto as Schedule
1 are incorporated herein by reference.

                                    ARTICLE V

                       MAINTENANCE OF RECORDS AND REPORTS

      During the Term of this Agreement and for a period of two (2) years
following the expiration or termination of this Agreement, the Parties agree to
maintain complete and accurate accounting records, in a form substantially in
accordance with standard accounting practices, substantiating the compensation,
reimbursements, overhead rate, and late interest, if any, invoiced by VaxGen for
Services rendered during the term of this Agreement, and listing the invoices
received by VCI and payments made pursuant to such invoices. These records shall
be kept at the Parties' principal place of business, and shall be made available
for inspection and copying during regular business hours by an independent
accountant retained by the Party seeking inspection at such Party's sole
expense.

                                   ARTICLE VI

                              TERM AND TERMINATION

6.1 Term of Agreement. The term of this Agreement will commence on the Effective
Date and will continue for a period of five (5) years until the fifth
anniversary of the Effective Date, unless earlier terminated as set forth
herein.

6.2 Termination at Will. Either Party may terminate this Agreement at will upon
the provision of ninety (90) days prior written notice to the other Party.

6.3 Termination for Cause. Failure by either Party to comply with any of its
material obligations set forth in this Agreement shall entitle the
non-defaulting Party to give the defaulting Party a notice specifying the nature
of the default and requiring the defaulting Party to make good its default. If
such default is not cured within thirty (30) days after such notice, the
non-defaulting Party shall be entitled, without prejudice to any of its other
rights under this Agreement or available under law or in equity, to terminate
this agreement effective upon a notice of termination to the defaulting Party.
Such termination shall not relieve the breaching Party from any obligations,
which are expressly indicated to survive the termination or expiration of this
Agreement.

6.4 Termination for Insolvency or Bankruptcy. Section 9.3 of the License
Agreement, attached hereto as Schedule 1, shall be incorporated herein by
reference.

6.5 Expiration or Termination. Upon expiration or termination of this Agreement,
the performance of any and all Services shall cease. Compensation for all
Services rendered up to the date of expiration or termination shall be due and
payable, and if overpayment has occurred, then such overpayment amounts shall be
deducted and the overpayment shall be refunded within sixty (60) days of such
termination. In addition, the reimbursement of all expenses incurred pursuant to
Section 2.3, and all outstanding

                                       5
<PAGE>

financial obligations incurred on behalf of VCI, on or before the date of
expiration or termination, shall be due and payable on or before the fifteenth
(15th) day following any such expiration or termination.

6.6 Survival of Terms. The following terms will survive expiration or
termination of this Agreement: Sections 2.2, 2.3, 2.4, 2.5, and 6.5, and
Articles III, IV, V, VII, VIII, and IX.

                                   ARTICLE VII

                                 CONFIDENTIALITY

      Section 6.1 of License Agreement, which is attached hereto as Schedule 1,
is incorporated herein by reference.

                                  ARTICLE VIII

                                    LANGUAGE

      This Agreement is written in the English language, which language shall
prevail over any translation thereof.

                                   ARTICLE IX

                                  MISCELLANEOUS

9.1 Force Majeure. Section 10.11 of the License Agreement, which is attached
hereto as Schedule 1, is incorporated herein by reference.

9.2 Binding Effect and Assignment. This Agreement shall be binding upon and
inure to the benefit of the Parties hereto and their respective permitted
successors and assigns, subject to the remainder of this Section 9.2. This
Agreement shall not be assignable by either Party in whole or in part without
the other Party's prior consent in its sole discretion, except that either Party
may assign this Agreement in whole or in part without the other Party's consent
in connection with any consolidation, merger redemption, put or sale of stock,
conveyance of substantially all of the assigning Party's assets, or
change-of-control transaction that involves the assigning Party.

9.3 Governing Law; Disputes. Sections 10.2 and 10.5 of the License Agreement,
which is attached hereto as Schedule 1, shall be incorporated herein by
reference.

9.4 Notices. Any notice, request, delivery, demand, report, accounting, approval
or consent required or permitted to be given under this Agreement shall be in
writing and shall be deemed sufficiently given on the same day as delivery if
delivered in person or transmitted by telecopier (with confirmed answer-back) in
any case by 5:00 p.m. local time, on the next business day if sent by overnight
courier service, and in three business

                                       6
<PAGE>

days if sent by registered or certified mail, in any case addressed to the Party
to whom it is directed at its address shown below or such other address as such
Party shall have last given by notice to the other Party in accordance with this
Section:

If to VaxGen, addressed to:      VaxGen, Inc.
                                 1000 Marina Boulevard
                                 Brisbane, CA   U.S.A.  94005-1841
                                 Attn: Dr. Lance K. Gordon
                                 Facsimile: (650) 624-1003

If to VCI, addressed to:         VaxGen-Celltrion, Inc.
                                 c/o VaxGen, Inc.
                                 1000 Marina Boulevard
                                 Brisbane, CA   U.S.A.  94005-1841
                                 Attn: James P. Panek
                                 Facsimile: (650) 624-1001

9.5 Entire Understanding. This Agreement, along with the License Agreement,
effective as of June 7, 2002, which is attached hereto as Schedule 1, and the
other Schedules, contains the entire understanding of the Parties with respect
to the subject matter contained herein, and supercedes all prior understandings
between the Parties, whether written or oral, regarding the same matter. There
are no restrictions, promises, covenants or understandings other than those
expressly set forth herein, and no rights or duties on the part of either Party
are to be implied or inferred beyond those expressly herein provided for. The
Parties hereto may, from time to time during the term of this Agreement, modify,
vary, or alter any of the provisions of this Agreement but only by written
agreement duly executed by the Parties.

9.6 Severance. Section 10.7 of the License Agreement, which is attached hereto
as Schedule 1, shall be incorporated herein by reference.

9.7 Publicity. VCI and VaxGen shall consult and obtain mutual consent before
making any public announcement concerning this Agreement, the subject matter
hereof or use of the other Party's name, except for information that is already
in the public domain or where the nature of such information has been previously
approved for disclosure (in which case this Section 10.7 will no longer apply to
that previously approved information).

9.8 Independent Contractors. Section 10.13 of the License Agreement, which is
attached hereto as Schedule 1, shall be incorporated herein by reference.

9.9 Waiver. Section 10.6 of the License Agreement, which is attached hereto as
Schedule 1, shall be incorporated herein by reference.

9.10 Third Party Beneficiaries. This Agreement does not create, and shall not be
construed to create, any rights enforceable by any person not a Party to this
Agreement.

                                       7
<PAGE>

9.11 Headings. Section 10.12 of the License Agreement, which is attached hereto
as Schedule 1, is incorporated herein by reference.

9.12 Counterparts. This Agreement may be executed in counterparts, each of which
shall be deemed an original for all purposes, but all of which together shall
constitute one and the same instrument.

                            [Signature Page Follows]

                                       8
<PAGE>

      IN WITNESS WHEREOF, the undersigned are duly authorized to execute this
Agreement on behalf of VaxGen and VCI, as applicable.

VAXGEN, INC.                           VAXGEN-CELLTRION, INC.

("VaxGen")                             ("VCI")

By:                                    By:

Print Name:                            Print Name:

Title:                                 Title:

                                       9
<PAGE>

                                   SCHEDULE 1

                                LICENSE AGREEMENT

                                       10
<PAGE>

                                   SCHEDULE 2

                                  OVERHEAD RATE

Facility Costs (Office Space Only)                              [*]
           Indirect Labor
                     Facilities
                     Office Services
                     Purchasing
           Office Rent
           Utilities
           Security
           General Insurance
           Facility Repairs and Maintenance
           Depreciation on Office Equipment

Benefits                                                        [*]
           Medical Insurance
           Dental Insurance
           Vision Insurance
           Life Insurance
           Long Term Disability
           Short Term Disability
           Employer Taxes
           Vacation

Operating Expenses                                              [*]
           Telecommunication
           Office Supplies
           Postage and Couriers
           Software License
           Equipment Rental (Copiers, Cubicles)
           Office Equipment Repair and Maintenance
           Print and Reproductions

Other Indirect Labor
           Finance and Administration                           [*]
           Corporate Communications                             [*]
           Human Resources                                      [*]
           Information Technology                               [*]

Total Overhead Allocation                                       [*]

[*] Denotes confidential treatment requested. A complete version of this exhibit
has been filed separately with the Securities and Exchange Commission

                                       11EXHIBIT 10.46

STANDARD FORM 26 (REV. 4-85) NSN 7540-01-152-8069 0MB No. 0990-0115  RFP 99-21

AWARD/CONTRACT

1.    THIS CONTRACT IS A RATED ORDER > RATING      PAGE OF           PAGES

      UNDER IPAS (15 CFR 350)        >                1                27

2.    CONTRACT (Proc. inst. ident.) No.
      N01-AI-95373

3.    EFFECTIVE DATE

      July 9, 1999

4.    REQUISITION/PURCHASE REQUEST/PROJECT NO.

      091

5.    ISSUED BY                                         CODE 2668-95373
                                                             -----------
      National Institutes of Health
      Contract Management Branch, NIAID
      Room 2230
      6700-B Rockledge Dr., MSC 7612
      Bethesda, Maryland 20892-7612

6.    ADMINISTERED BY (If other than item 5)           CODE
                                                            ------------
7.    NAME AND ADDRESS OF CONTRACTOR (No., street, city, country, State and ZIP
      Code)

      VaxGen Incorporated
      1000 Marina Blvd., Suite 200
      Brisbane, CA 94005-1841

8.    DELIVERY

      |_| FOB ORIGIN  |X| OTHER (See below)

9.    DISCOUNT FOR PROMPT PAYMENT

      N/A

10.   SUBMIT INVOICES                                 ITEM

      (4 copies unless otherwise specified) TO THE >  G.5
      ADDRESS SHOWN IN

      CODE                                    FACILITY CODE
          ------------                                      ------------
11.   SHIP TO/MARK FOR

      See Article F.1.

12.   PAYMENT WILL BE MADE BY                          CODE
                                                            ------------
      See Article G.5.

13.   AUTHORITY FOR USING OTHER THAN FULL AND OPEN COMPETITION
        N/A

      |_| 10 U.S.C. 2304 (c) (_)       |_| 41 U.S.C 253 (c) (_)

14.   ACCOUNTING AND APPROPRIATION DATA

      EIN# 1-943236309-A1 SOC# 25.55 DOC# 300N1AI9S373A
      CAN# 9-8425674

      OBLIGATION OF FUNDS IN THE AMOUNT OF $200,000

15A.  ITEM NO.

15B.  SUPPLIES/SERVICES

15C.  QUANTITY

15D.  UNIT

15E.  UNIT PRICE

15F.  AMOUNT

Research & Development Contract                       FY 99  200,000

Title; HIV VACCINE PRODUCTION
Period: July 9, 1999 through July 8, 2006
Amount allotted: $200,000
Contract Type: IDIQ (FFP, CR, CPFF, TIME & MATERIALS, LABOR HOUR)

15G.  TOTAL AMOUNT OF CONTRACT -> $ 200,000

16.   TABLE OF CONTENTS

<TABLE>
<CAPTION>
|X|  SEC.  DESCRIPTION                           PAGE(S)     |X|  SEC.     DESCRIPTION                                  PAGE(S)
---  ----  -----------                           -------     ---  ---      -----------                                  -------
           PART I - THE SCHEDULE                                           PART II - CONTRACT CLAUSES
           ---------------------                                           --------------------------

<S>  <C>   <C>                                     <C>        <C>    <C>   <C>                                               <C>
X    A     SOLICITATION/CONTRACT FORM               1         |X|    I     CONTRACT CLAUSES                                  20

X    B     SUPPLIES OR SERVICES AND PRICES/COSTS    4         PART III - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACH.

X    C     DESCRIPTION/SPECS./WORK STATEMENT        6         |X|    J     LIST OF ATTACHMENTS                               26

X    D     PACKAGING AND MARKING                    9         PART IV  - REPRESENTATIONS AND INSTRUCTIONS

X    E     INSPECTION AND ACCEPTANCE                9         |X|    K     REPRESENTATIONS, CERTIFICATIONS AND               27

X    F     DELIVERIES OR PERFORMANCE                9                      OTHER STATEMENTS OF OFFEPORS

X    G     CONTRACT ADMINISTRATION DATA            10         |_|    L     INSTRS., CONDS., AND NOTICES TO OFFERORS

X    H     SPECIAL CONTRACT REQUIREMENTS           14         |_|    M     EVALUATION FACTORS FOR AWARD
</TABLE>

          CONTRACTING OFFICER WILL COMPLETE ITEM 17 OR 18 AS APPLICABLE
-------------------------------------------------------------------------------

17.   |X| CONTRACTOR'S NEGOTIATED AGREEMTNT (Contractor is required to sign this
      document and return 3 copies to issuing office.) Contractor agrees to
      furnish and deliver all items or perform all the services set forth or
      otherwise identified above and on any continuation sheets for the
      consideration stated herein. The rights and obligations of the parties to
      this contract shall be subject to and governed by the following documents:
      (a) this award/contract, (b) the solicitation, if any, and (c) such
      provisions, representations, modifications, and specifications, as are
      attached or incorporated by reference herein. (Attachments are listed
      herein.)

18.   |_| AWARD (Contractor is not required to sign this document.) Your offer
      on Solicitation Number ______________________ including the full additions
      or changes made by you which additions or changes are set forth in full
      above, is hereby accepted as to the items listed above and on any
      continuation sheets. This award consummates the contract which consists of
      the following documents: (a) the Government's solicitation and your offer,
      and (b) this award/contract. No further contractual document is necessary.

19A.  NAME AND TITLE OF SIGNER (Type or print)

      Carter A. Lee

19B.  NAME OF CONTRACTOR

      BY  [GRAPHIC OMITTED]
      ---------------------------------------
      (Signature of person authorized to sign)

19C.  DATE SIGNED

      06/28/99

20A.  NAME OF CONTRACTING OFFICER

      Lawrence M. Butler, Contracting Officer
      Contract Management Branch, NIAID, NIH

20B.  UNITED STATES OF AMERICA

           /s/ Lawrence M. Butler
      ----------------------------------
      (Signature of Contracting Officer)

20C.  DATE SIGNED

      06/30/99

<PAGE>

                                                       Contract No. NO1-AI-95373

                      DETAILED TABLE OF CONTRACT CONTENTS

PART I - THE SCHEDULE
<TABLE>

<S>                                                                                              <C>
      SECTION A - SOLICITATION/CONTRACT FORM ................................................... 1
      SECTION B - SUPPLIES OR SERVICES AND PRICES/COSTS ........................................ 4
            ARTICLE B.1. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES ............................. 4
            ARTICLE B.2. PRICES ................................................................ 4
            ARTICLE B.3. PROVISIONS APPLICABLE TO DIRECT COSTS ................................. 4
            ARTICLE B.4. ADVANCE UNDERSTANDINGS ................................................ 5
      SECTION C - DESCRIPTION/SPECIFICATIONS/WORK STATEMENT .................................... 6
            ARTICLE C.1. [DESCRIPTION-SPECIFICATION-WORK STATEMENT-STATEMENT OF WORK] .......... 6
            ARTICLE C.2. REPORTING REQUIREMENTS ................................................ 6
            ARTICLE C.3. INVENTION REPORTING REQUIREMENT ....................................... 8
      SECTION D - PACKAGING, MARKING AND SHIPPING .............................................. 9
      SECTION E - INSPECTION AND ACCEPTANCE .................................................... 9
      SECTION F - DELIVERIES OR PERFORMANCE .................................................... 9
            ARTICLE F.1. DELIVERIES ............................................................ 9
            ARTICLE F.2. CLAUSES INCORPORATED BY REFERENCE ..................................... 10
      SECTION G - CONTRACT ADMINISTRATION DATA ................................................. 10
            ARTICLE G.I. PROJECT OFFICER ....................................................... 10
            ARTICLE G.2. KEY PERSONNEL ......................................................... 11
            ARTICLE G.3. TASK ORDER PROCEDURES ................................................. 11
            ARTICLE G.4. INDEFINITE DELIVERY CONTRACT PAYMENT METHOD ........................... 12
            ARTICLE G.5. INVOICE SUBMISSION .................................................... 13
            ARTICLE G.6. INDIRECT COST RATES ................................................... 13
            ARTICLE G.7. GOVERNMENT PROPERTY ................................................... 13
            ARTICLE G.8. POST AWARD EVALUATION OF PAST PERFORMANCE ............................. 14
      SECTION H - SPECIAL CONTRACT REQUIREMENTS ................................................ 14
            ARTICLE H.1. REIMBURSEMENT OF COSTS FOR INDEPENDENT RESEARCH AND DEVELOPMENT
               PROJECTS ........................................................................ 14
            ARTICLE H.2. HUMAN SUBJECTS ........................................................ 14
            ARTICLE H.3. RESTRICTION FROM USE OF HUMAN SUBJECTS ................................ 14
            ARTICLE H.4. HUMAN MATERIALS ....................................................... 15
            ARTICLE H.5. CONTINUED BAN ON FUNDING OF HUMAN EMBRYO RESEARCH ..................... 15
            ARTICLE H.6. NEEDLE EXCHANGE ....................................................... 15
            ARTICLE H.7. INTRODUCTION OF RODENTS AND RODENT PRODUCTS ........................... 15
            ARTICLE H.8. ANIMAL WELFARE ASSURANCE .............................................. 16
            ARTICLE H.9. RESTRICTION FROM USE OF LIVE VERTEBRATE ANIMALS ....................... 16
            ARTICLE H.10. SALARY RATE LIMITATION LEGISLATION PROVISIONS ........................ 16
            ARTICLE H.11. EPA ENERGY STAR REQUIREMENTS ......................................... 16
            ARTICLE H.12. PUBLICATION AND PUBLICITY ............................................ 17
            ARTICLE H.13. PRESS RELEASES ....................................................... 17
            ARTICLE H.14. TASK ORDER/DELIVERY ORDER CONTRACT OMBUDSMAN ......................... 17
            ARTICLE H.15. REPORTING MATTERS INVOLVING FRAUD, WASTE AND ABUSE ................... 17
            ARTICLE H.16. YEAR 2000 COMPLIANCE ................................................. 18
PART II- CONTRACT CLAUSES ...................................................................... 20

      SECTION I - CONTRACT CLAUSES ............................................................. 20
            ARTICLE I.1 GENERAL CLAUSES FOR A COST-REIMBURSEMENT RESEARCH AND DEVELOPMENT
                CONTRACT ....................................................................... 21
            ARTICLE I.2. AUTHORIZED SUBSTITUTION OF CLAUSES .................................... 24
            ARTICLE I.3. ADDITIONAL CONTRACT CLAUSES ........................................... 24
            ARTICLE I.4. ADDITIONAL FAR CONTRACT CLAUSES INCLUDED IN FULL TEXT ................. 25
</TABLE>

                                        2

<PAGE>

                                                       Contract No. NO1-AI-95373
<TABLE>

<S>                                                                                              <C>
PART III ....................................................................................... 26

      SECTION J - LIST OF ATTACHMENTS .......................................................... 26
            1. Statement of Work................................................................ 26
            2. Invoice/Financing Request Instructions for NIH Cost-Reimbursement Type Contracts. 26
            3. Safety and Health................................................................ 26
            4. Procurement of Certain Equipment................................................. 26
PART IV ........................................................................................ 27
      SECTION K - REPRESENTATIONS AND CERTIFICATIONS ........................................... 27
            1. Representations and Certifications .............................................. 27
</TABLE>

                                       3
<PAGE>

                                                       Contract No. NO1-AI-95373

SECTION B - SUPPLIES OR SERVICES AND PRICES/COSTS

ARTICLE B.1. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES

The purpose of this contract is to develop candidate vaccines including scale-up
and production of GLP/GMP lots suitable for human use and to perform the
necessary characterization tests required for release of vaccines for clinical
use.

ARTICLE B.2. PRICES

a.    The contractor shall be reimbursed by the Government in an amount not less
      than a total of $200,000 nor more than a total of $76,624,622 for
      successful performance of this contract.

b.    If an order for at least the minimum amount is not issued within 12 months
      of award, the funds obligated at the time of award shall be used to
      satisfy the minimum guarantee.

c.    The prices set forth in this ARTICLE B.2. will cover the contract period
      from July 9, 1999 through July 8, 2006.

ARTICLE B.3. PROVISIONS APPLICABLE TO DIRECT COSTS

a.    Items Unallowable Unless Otherwise Provided

      Notwithstanding the clauses, ALLOWABLE COST AND PAYMENT, and FIXED FEE,
      incorporated in this contract, unless authorized in writing by the
      Contracting Officer, the costs of the following items or activities shall
      be unallowable as direct costs:

      (1)   Acquisition, by purchase or lease, of any interest in real property;

      (2)   Special rearrangement or alteration of facilities;

      (3)   Purchase or lease of any item of general purpose office furniture or
            office equipment regardless of dollar value. (General purpose
            equipment is defined as any items of personal property which are
            usable for purposes other than research, such as office equipment
            and furnishings, pocket calculators, etc.);

      (4)   Travel to attend general scientific meetings;

      (5)   Foreign travel;

      (6)   Patient care costs;

      (7)   Accountable Government property (defined as both real and personal
            property with an acquisition cost of $1,000 or more and a life
            expectancy of more than two years) and "sensitive items" (defined
            and listed in the Contractor's Guide for Control of Government
            Property), 1990, regardless of acquisition value.

      (8)   Subcontracts

b.    Travel Costs

      Domestic Travel

      The Contractor shall invoice and be reimbursed for all travel costs in
      accordance with Federal Acquisition Regulations (FAR) 31.205-46.

                                        4

<PAGE>

                                                       Contract No. NO1-AI-95373

ARTICLE B.4. ADVANCE UNDERSTANDINGS

Other provisions of this contract notwithstanding, approval of the following
items within the limits set forth is hereby granted without further
authorization from the Contracting Officer.

a.    GLP/GMP Compliance

      The Contractor certifies that all laboratory facilities used in the
      production of vaccine products as a result of task orders issued under the
      subject contract are GLP/CMP compliant and adhere to the guidelines set
      forth for such compliance by the FDA.

b.    Indirect Costs

      (1)   In no event shall any costs for fringe benefits, R&D Overhead, or
            General and Administrative expenses billed under the subject
            contract be reimbursable until a negotiated agreement is in place
            with the Government.

      (2)   The Contractor shall complete all work in accordance with
            the Statement of Work, terms and conditions of this contract.

c.    Invoices - Cost and Personnel Reporting, and Variances from the Negotiated
      Budget

      (1)   The contractor agrees to provide a detailed breakdown on invoices of
            the following cost categories for each task order:

            (a)   Direct Labor - List individuals by name, title/position,
                  hourly/annual rate, level of effort, and amount claimed.

            (b)   Fringe Benefits - Cite rate and amount

            (c)   Overhead - Cite rate and amount

            (d)   Materials & Supplies - Include detailed breakdown when total
                  amount is over $1,000.

            (e)   Travel - Identify travelers, dates, destination, purpose of
                  trip, and amount. Cite COA, if appropriate. List separately,
                  domestic travel, general scientific meeting travel, and
                  foreign travel.

            (f)   Equipment (Attach HHS. 565 and cite COA number for each item
                  if applicable)

            (g)   Subcontract (List each subcontract as a separate line item)

            (h)   Other Expenses - Provide breakdown of these items and required
                  authorizations if applicable.

            (i)   G&A - Cite rate and amount.

            (j)   Total Cost

            (k)   Fixed Fee

            (1)   Total CPFF

            Monthly invoices must include the cumulative total expenses to date,
            adjusted (as applicable) to show any amounts suspended by the
            Government.

      (2)   The contractor agrees to immediately notify the contracting officer
            in writing if there is an anticipated overrun (any amount) or
            unexpended balance (greater than 10 percent) of the amount allotted
            to the contract, and the reasons for the variance. Also refer to the
            requirements of the Limitation of Funds and Limitation of Cost
            Clauses in the contract.

                                       5

<PAGE>

                                                       Contract No. NO1-AI-95373

h.    Task Order Provisions

      (1)   It is anticipated that all task orders shall be awarded on a
            cost-plus-fixed basis. Clauses and Articles applicable to a
            cost-plus-fixed-fee type contract, as appropriate, shall be
            incorporated into this contract as each task order is awarded.

      (2)   The requirements set forth in FAR Clause 52.219-14, Limitation on
            Subcontracting (DECEMBER 1996), incorporated by reference in this
            contract in Part II, Article I.3., shall be applicable to EACH
            individual task order as they are awarded.

SECTION C - DESCRIPTION/SPECIFICATIONS/WORK STATEMENT

ARTICLE C.1. [DESCRITPION-SPECIFICATION-WORK STATEMENT-STATEMENT OF WORK]

Independently and not as an agent of the Government, the Contractor shall
furnish all the necessary services, qualified personnel, material, equipment,
and facilities, not otherwise provided by the Government as needed to perform
the Statement of Work, SECTION J, ATTACHMENT 1, dated July 9, 1999, attached
hereto and made apart of this contract.

ARTICLE C.2. REPORTING REQUIREMENTS

In addition to those reports required by the Statement of Work and other terms
of the Contract, the Contractor shall prepare and submit the following reports
in the manner stated below. Reports will be required for Contractors with active
Task Orders throughout the period of the Contract.

a.    Milestone Reports (each task order will include guidelines for milestone
      reports).

      Upon the completion of each milestone as indicated in the Task Order, the
      Contractor shall submit three (3) copies of a milestone report as
      described below. Two (2) copies should be submitted to the Project Officer
      and one (1) copy to the Contracting Officer. The milestone report should
      be factual and concise and consist of the following:

      1)    A title page containing:

            (a)   Contract number and title

            (b)   Sequence of report; e.g., "Year 1, 2nd Milestone Report"

            (c)   Period of performance being reported

            (d)   Contractor's name and address

            (e)   Date of submission

      2)    Reports shall include, but are not limited to the following
            information:

            (a)   A report detailing the actions taken to achieve the milestone.

            (b)   A report of all products, procedures and outcomes achieved.

            (c)   Graphs and tables of data obtained.

            (d)   A detailed budget report with invoices and cost justifications
                  related to achieving this milestone.

            (e)   Other information as may be required by the Project Officer.

                                       6

<PAGE>

                                                       Contract No. NO1-AI-95373

b.    Quarterly Progress Reports

      By the fifteenth (15) working day of the month following the end of each
      quarter, the Contractor shall submit three (3) copies of a quarterly
      progress report as described below. Two (2) copies should be submitted to
      the Project Officer and one (1) copy to the Contracting Officer. The
      quarterly report should be factual and concise and consist of the
      following:

      1)    A title page containing:

            (a)   Contract number and title

            (b)   Sequence of report; e.g., "Year 1, 2nd Quarterly Report"

            (c)   Period of performance being reported

            (d)   Contractor's name and address

            (e)   Date of submission

      2)    Reports shall include, but are not limited to the following
            information:

            (a)   A brief introduction covering the objective and scope of the
                  contract effort.

            (b)   Progress and report of problems and proposed solutions in
                  development/production of a vaccine for Task Orders
                  issued under Part A.

            (c)   Progress and report of problems and solutions for safety and
                  inmnunogenicity testing for Task Orders issued under Part B.

            (d)   Progress and report of problems and solutions for FDA
                  submissions for Task Orders issued under Part C.

            (e)   Selected other information as may be required by the Project
                  Officer.

      3)    A quarterly report is not due when an annual report is due.

c.    Annual Reports

      On or before the last day of the Contract year, the Contractor shall
      submit three (3) copies of an annual report. Two (2) copies shall be
      submitted to the Project Officer and one (1) copy shall be submitted to
      the Contracting Officer. The annual report shall summarize progress for
      the entire contract year, following the same format as for the quarterly
      reports, and shall take the place of the fourth quarterly report. In
      addition, it should include abstracts, manuscripts in progress or
      submitted, and publications resulting from the performance of work under
      the contract.

d.    Individual Task Order Final Reports

      The contractor shall submit three (3) copies of each Task Order final
      report, two (2) copies to the Project Officer and one (1) copy to the
      Contracting Officer, which will summarize the results of the each
      completed Task Order. This report will be in sufficient detail to explain
      comprehensively the results achieved and will be submitted no later than
      the completion date of the Task Order.

      The final report shall contain:

      1)    Title Page as described above in paragraph a.1).

      2)    Introduction covering the purpose and scope of the active Task
            Order.

      3)    Description of the overall progress of the active Task Order.
            Descriptions shall include pertinent data in tables or graphs as
            appropriate to present significant results achieved, conclusions
            resulting from analysis, and a scientific evaluation of the data
            accrued under the active task.

      4)    Copies of any abstracts, manuscripts, and publications.

                                       7

<PAGE>

                                                       Contract No. NO1-AI-95373

e.    Other Deliverables

      The Contractor, at the request of the Project Officer, shall deliver to
      the Government or its designee by the completion date of the Task Order,
      the following items:

      PART A:

            (a)   Test lots of vaccine products, as they are produced.

            (b)   cGMP quality pilot lots of candidate vaccine products and
                  adjuvants, as they are produced.

            (c)   All vaccine candidates and adjuvants in various stages of
                  production at termination of the contract with detailed
                  information on them.

            (d)   A compete listing of accurate and updated information on
                  design, development and production including activities of the
                  Contractor, computerized data files, original data and any
                  necessary information related thereto.

            (e)   A complete list of accurate and updated information on
                  activities of subcontracts.

            (f)   Labeled and inventoried paper files.

            (g)   Government-owned equipment and property.

      PART B:

            (a)   All data obtained from safety and immunogenicity trials.

            (b)   All vaccine products, adjuvants, etc., remaining from these
                  studies.

      PART C:

            (a)   All files pertaining to the contract at the request of the
                  Project Officer.

            (b)   Copies of all FDA submissions.

f.    If the Contractor becomes unable to deliver the reports or other
      deliverables here specified within the period of performance because of
      unforeseen difficulties, notwithstanding the exercise of good faith and
      diligent efforts in performance of the work, the Contractor shall give the
      Contracting Officer immediate written notice of anticipated delays with
      reasons therefore at the address given below in section F.

ARTICLE C.3. INVENTION REPORTING REQUIREMENT

      All reports and documentation required by [FAR Clause 52.227-11/FAR Clause
      52.227-11 (Deviation)/FAR Clause 52.227-13] including, but not limited to,
      the invention disclosure report, the confirmatory license, and the
      government support certification, shall be directed to the Office of
      Extramural Inventions and Technology Resources Branch, OPERA, NIH, 6701
      Rockledge Drive, Room 3190, Bethesda, Maryland 20892-7750 (Telephone:
      301-435-1986). In addition, one copy of the annual utilization report, and
      a copy of the final invention statement, shall be submitted do the
      Contracting Officer at the address listed below. The final invention
      statement (see FAR 27.303(a)(2)(ii)) shall be submitted within 90 days
      after contract expiration to the following address:

      Contracting Officer
      National Institutes of Health
      Contract Management Branch, CMB
      6700-B Rockledge Drive, Room 2230 MSC 7612
      Bethesda, Maryland 20893-7612

                                        8

<PAGE>

                                                       Contract No. NO1-AI-95373

To assist contractors in complying with invention reporting requirements of the
clause, the NIH has developed "Interagency Edison," an electronic invention
reporting system. Use of Interagency Edison is encouraged as it streamlines the
reporting process and greatly reduces paperwork. Access to the system is through
a secure interactive Web site to ensure that all information submitted is
protected. Interagency Edison and information relating to the capabilities of
the system can be obtained from the Web (http://www.iedison.gov), or by
contacting the Office of Extramural Inventions and Technology Resources Branch,
OPERA, NIH.

SECTION D - PACKAGING, MARKING AND SHIPPING

All deliverables required under this contract shall be packaged, marked and
shipped in accordance with Government specifications. At a minimum, all
deliverables shall be marked with the contract number and name. The Contractor
shall guarantee that all required materials shall be delivered in immediate
usable and acceptable condition.

SECTION E - INSPECTION AND ACCEPTANCE

a.    The Contracting Officer or the duly authorized representative will perform
      inspection and acceptance of materials and services to be provided.

b.    For the purpose of this ARTICLE, the Project Officer is the authorized
      representative of the Contracting Officer.

c.    Inspection and acceptance will be performed at the address listed for the
      Project Officer in Section C, Article G.2.

      Acceptance may be presumed unless otherwise indicated in writing by the
      Contracting Officer or the duly authorized representative within 30 days
      of receipt.

d.    This contract incorporates the following clause by reference, with the
      same force and effect as if it were given in full text. Upon request, the
      Contracting Officer will make its full text available.

      FAR Clause No. 52.246-9, INSPECTION OF RESEARCH AND DEVELOPMENT (SHORT
      FORM) (APRIL 1984).

SECTION F - DELIVERIES OR PERFORMANCE

ARTICLE F.1. DELIVERIES

Satisfactory performance of the final contract shall be deemed to occur upon
delivery and acceptance by the Contracting Officer, or the duly authorized
representative, of the following items in accordance with the stated delivery
schedule:

a.    The items specified below as described in SECTION C, ARTICLE C2, will be
      required to be delivered F.O.B. Destination as set forth in FAR 52.247-35,
      F.O.B. DESTINATION, WITHIN CONSIGNEES PREMISES (APRIL 1984), and in
      accordance with and by the dates specified below and any specifications
      stated in SECTION D, PACKAGING, MARKING AND SHIPPING, of the contract:

Item                      Description           Quantity    Delivery Schedule

(a)                       Milestone Report         3        To Be Determined
(b)                       Quarterly Report         3        To Be Determined
(c)                       Annual Report            3        To Be Determined
(d)                       Final Report             3        At The Completion Of
                                                            Each Task

                                        9

<PAGE>

                                                       Contract No. NO1-AI-95373

b.    The above items shall be addressed and delivered to:

      Addressee                                   Deliverable Item No.  Quantity

      Project Officer,                                  (a)                 2
      PRB, VPRP, NIAID, NIH                             (b)                 2
      6700-B Rockledge Drive, Room 4106 MSC 7628        (c)                 2
      Bethesda, MD 20892-7628                           (d)                 2

      Contracting Officer,                              (a)                 1
      CMB, DEA, NL&ID, NIH                              (b)                 1
      6700-B Rockledge Drive, Room 2230 MSC 7612        (c)                 1
      Bethesda, Maryland 20892-7612                     (d)                 1

ARTICLE F.2. CLAUSES INCORPORATED BY REFERENCE, FAR 52.252-2 (FEBRUARY 1998)

This contract incorporates the following clause by reference, with the same
force and effect as if it were given in full text. Upon request, the Contracting
Officer will make its full text available. Also, the full text of a clause may
be accessed electronically at this address: http://www.arnet.gov/far/.

FEDERAL ACQUISiTION REGULATION (48 CFR CHAPTER 1) CLAUSE:

      52.242-15, Stop Work Order (AUGUST 1989) with ALTERNATE I (APRIL 1984).

SECTION G - CONTRACT ADMINISTRATION DATA

ARTICLE G.1. PROJECT OFFICER

The following Project Officer will represent the Government for the purpose of
this contract:

      Chris Butler, Ph.D.
      Project Officer,
      PRB, VPRP, NIAID, NIH
      6700-B Rockledge Drive, Room 4106 MSC 7628
      Bethesda, Maryland 20892-7628

The Project Officer is responsible for: (1) monitoring the Contractor's
technical progress, including the surveillance and assessment of performance and
recommending to the Contracting Officer changes in requirements; (2)
interpreting the Statement of Work and any other technical performance
requirements; (3) performing technical evaluation as required; (4) performing
technical inspections and acceptances required by this contract; and (5)
assisting in the resolution of technical problems encountered during
performance.

The Contracting Officer is the only person with authority to act as agent of the
Government under this contract. Only the Contracting Officer has authority to:
(1) direct or negotiate any changes in the Statement of Work; (2) modify or
extend the period of performance; (3) change the delivery schedule; (4)
authorize reimbursement to the Contractor any costs incurred during the
performance of this contract; or (5) otherwise change any terms and conditions
of this contract.

The Government may unilaterally change its Project Officer designation.

10

<PAGE>

                                                       Contract No. NO1-AI-95373

ARTICLE G.2. KEY PERSONNEL

Pursuant to the Key Personnel clause incorporated in this contract, the
following individual(s) is/are considered to be essential to the work being
performed hereunder:

      Name                                Title
      Phiilip W. Berman, Ph.D.            Principal Investigator

ARTICLE G.3. TASK ORDER PROCEDURES

In providing services under the contract, the following procedures shall apply
to the award of task orders.

All work required under the contract shall be authorized through the execution
of a bilateral modification to the contract. Each modification will obligate the
necessary funds to complete the task order and will include the work statement
of the task order as an attachment. Task orders may be issued at any time within
the contract period.

When the Government elects to fill a requirement that is estimated to exceed
$2,500, the Contracting Officer shall provide a Task Order Request (TOR) to the
awardees that received contacts for the particular Part for which responses are
being solicited. A TOR shall, at a minimum, include a Statement of Work,
evaluation factors, specific reporting requirements, deliverables and delivery
schedule, the relevant importance of technical and cost factors, and any special
instructions.

Business proposals shall include direct and indirect costs necessary for
performing the proposed task. Task order proposals shall generally be limited to
a total of 20 pages, including attachments.

Within the time allowed for proposal preparation (time allowed for proposal
preparation and submission will vary depending on the task) which will be
designated in the task order request, Contractors shall submit their proposals
in response to a task order request, which shall include, but not necessarily be
limited to the following information:

      (i) A statement of the contractor's clear understanding of the task
      requirements;

      (ii) A statement of technical and managerial resources and expertise the
      contractor can provide to satisfy the requirement;

      (iii) An approach to perform the work;

      (iv) The labor category necessary, and the numbers of hours for each labor
      category necessary, and an explanation of the rationale for determining
      hours;

      (v) Resumes with identification of the actual personnel proposed for the
      work;

      (vi) A schedule of performance identifying major milestones, deliverables
      and deliver date, and task completion; and

      (vii) an itemization of all costs, both direct and indirect, (i.e.
      personnel, fringe benefits, equipment, travel, supplies, other direct
      costs, overhead, etc.) necessary to complete the work.

The Government will evaluate proposals and conduct negotiations as necessary.
Task orders will be awarded to the contractor whose proposal is determined to be
the most advantageous to the Government based on the technical and price factors
specified in the TOR. The Government reserves the right to make an award on the
most favorable initial proposal without discussion.

The Contracting Officer is the only individual authorized to issue a TOR or
award a task order under the contract. Unless specifically authorized by the
Contracting Officer, the contractor shall not commence work on a requirement
until a modification to the contract has been fully executed.

                                       11

<PAGE>

                                                       Contract No. NO1-AI-95373

It is anticipated that task orders will be awarded within 30 calendar days from
receipt of task order proposals. Each task order shall, at a minimum, contain
the following information:

      o     Date of order

      o     Contract number and task order number sequentially; e.g.,
            N0l-A.I-12345 (Task order No. 001, 002, 003, etc).

      o     Description of services, and estimated cost.

      o     Performance period.

      o     Name and address of sponsoring office.

      o     Name of Contracting Officer's technical representative.

      o     Place of performance.

      o     Packaging, packing, and shipping instructions, if any,

      o     Accounting and appropriation data.

      o     Pricing Arrangements

            Contractors are required to propose hourly rates for each labor
            classification in their response to each TOR, with cost-reimbursable
            contract line items proposed for other elements of cost (i.e. fringe
            benefits, supplies, travel, equipment, other direct costs, indirect
            costs, fee, etc.). A 3% annual allowance for salary increases will
            be allowed for each of the subsequent years of each task if
            applicable. The subsequent negotiation of TORs issued to successful
            contractors eligible to submit a proposal under a TOR for which they
            qualify will focus on the number of hours proposed for each labor
            category and the estimated costs required for all other elements.

      o     Any other pertinent information.

No protest under FAR Subpart 323.1 is authorized in connection with the issuance
or proposed issuance of a task order under the contract except for a protest on
the grounds that the order increases the scope, period, or maximum value of the
contract. Task orders awarded under the contract are not subject to the
competition requirements of FAR Part 6.

ARTICLE G4. INDEFINITE DELIVERY CONTRACT PAYMENT METHOD

To initiate and receive prompt payment, the Contractor shall comply with the
following procedure:

      a.    A Task Order Number shall be given to you at the time the order is
            placed. The Contractor is cautioned not to accept an order unless
            one of these numbers is issued. Invoices shall cite the Contract
            Number and the Task Order Number for each order for which payment is
            being requested.

      b.    Invoices shall be submitted monthly to the address indicated below
            in ARTICLE G.5. iNVOICE SUBMISSION.

                                       12

<PAGE>

                                                       Contract No. NO1-AI-95373

ARTICLE G.5. INVOICE SUBMISSION

a.    Invoice/Financing Request Instructions for NIH Cost-Reimbursement Type
      Contacts NIH(RC)-1 are attached and made part of this contract. The
      instructions and the following directions for the submission of
      invoices/financing requests must be followed to meet the requirements of
      a "proper" payment request pursuant to FAR 32.9.

      (1)   Invoices/financing requests shall be submitted as follows:

            An original and two copies to the following designated billing
            office:

                  Contracting Officer
                  Contract Management Branch
                  National Institute of Allergy and
                    Infectious Diseases, NIH
                  6700-B Rockledge Drive, Room 2230
                  BETHESDA MD 20892-7612

      (2)   Inquiries regarding payment of invoices should be directed to the
            designated billing office, (301) 496-0192.

ARTICLE G.6. INDIRECT COST RATES

In accordance with Federal Acquisition Regulation (FAR) (48 CFR Chapter 1)
Clause 52.216-7(d)(2), Allowable Cost and Payment incorporated by reference in
this contract in Part II, Section I, the cognizant Contracting Officer
responsible for negotiating provisional and/or final indirect cost rates is
identified as follows:

            Director, Division of Financial Advisory Services
            Office of Contracts Management
            National Institutes of Health
            6100 Building, Room 6B05
            6100 EXECUTIVE BLVD MSC 7540
            BETHESDA MD 20892-7540

These rates are hereby incorporated without further action of the Contracting
Officer.

ARTICLE G.7. GOVERNMENT PROPERTY

a.    In addition to the requirements of the clause, GOVERNMENT PROPERTY,
      incorporated in Section I of this contact, the Contractor shall comply
      with the provisions of DHHS Publication, Contractor's Guide for Control of
      Government Property, (1990), which is incorporated into this contract by
      reference. Among other issues, this publication provides a summary of the
      Contractor's responsibilities regarding purchasing authorizations and
      inventory and reporting requirements under the contract. A copy of this
      publication is available upon request to the Contract Property
      Administrator.

      This contract's Contract Property Administrator is:

            Contracts Property Administrator
            Research Contracts Property Administration, NIH
            601 Building, Room 641E
            6011 EXECUTIVE BLVD MSC 7670
            BETHESDA MD 20852-7670
            (301) 496-6466

                                       13

<PAGE>

                                                       Contract No. NO1-AI-95373

ARTICLE G.8. POST AWARD EVALUATION OF PAST PERFORMANCE

Interim and final evaluations of contractor performance shall be conducted on
this contract in accordance with OFPP Policy Letter 92-5, issued January 11,
1993 and HHSAR 342.70002(c)(2)(iv). A final performance evaluation shall be
completed at the time of completion of work. In addition to the final
evaluation, interim evaluations will be prepared by the Project Officer and
submitted to the Contracting Officer. The Contracting Officer will concur by
initialing the appropriate block of the NIH Contractor Performance Report, and
will submit the document to the Contractor as soon as practicable. The
Contractor will be permitted thirty days to review the document and to submit
additional informnation or a rebutting statement.

SECTION H - SPECIAL CONTRACT REQUIREMENTS

ARTICLE H.1. REIMBURSEMENT OF COSTS FOR INDEPENDENT RESEARCH AND DEVELOPMENT
PROJECTS

The primary purpose of the Public Health Service (PHS) is to support and advance
independent research within the scientific comnmnunity. This support is provided
in the form of contracts and grants totaling approximately 7 billion dollars
annually. PHS has established effective, time tested and well recognized
procedures for stimulating and supporting this independent research by selecting
from multitudes of applications those research projects most worthy of support
within the constraints of its appropriations. The reimbursement through the
indirect cost mechanism of independent research and development costs not
incidental to product improvement would circumvent this competitive process.

To ensure that all research and development projects receive similar and equal
consideration, all organizations may compete for direct funding of independent
research and development projects they consider worthy of support by submitting
those projects to the appropriate Public Health Service grant office for review.
Since these projects may be submitted for direct funding, the Contractor agrees
that no costs for any independent research and development project, including
all applicable indirect costs, will be claimed under this contract.

ARTICLE H.2. HUMAN SUBJECTS

It is hereby understood and agreed that research involving human subjects shall
not be conducted under this contract, and that no material developed, modified,
or delivered by or to the Government under this contract, or any subsequent
modification of such material, will be used by the Contractor or made available
by the Contractor for use by anyone other than the Government, for experimental
or therapeutic use involving humans without the prior written approval of the
Contracting Officer.

ARTICLE H.3. RESTRICTION FROM USE OF HUMAN SUBJECTS

NOTICE: UNDER GOVERNING REGULATIONS, FEDERAL FUNDS ADMINISTERED BY THE
DEPARTMENT OF HEALTH AND HUMAN SERVICES SHALL NOT BE EXPENDED FOR RESEARCH
INVOLVING HUMAN SUBJECTS, AND INDIVIDUALS SHALL NOT BE ENROLLED IN SUCH
RESEARCH, WiTHOUT PRIOR APPROVAL BY THE OFFICE FOR PROTECTION FROM RESEARCH
RISKS (OPRR) OF AN ASSURANCE TO COMPLY WITH THE REQUIREMENTS OF 45 CFR 46 TO
PROTECT HUMAN RESEARCH SUBJECTS. THIS RESTRICTION APPLIES TO ALL COLLABORATING
SITES WITHOUT OPRR-APPROVED ASSURANCES, WHETHER DOMESTIC OR FOREIGN, AND
COMPLIANCE MUST BE ENSURED BY THE AWARDEE.

                                       14

<PAGE>

                                                       Contract No. NO1-AI-95373

ARTICLE H.4. HUMAN MATERIALS

It is understood that the acquisition and supply of all human specimen material
(including fetal material) used under this contract will be obtained by the
Contractor in full compliance with applicable State and Local laws and the
provisions of the Uniform Anatomical Gift Act in the United States and that no
undue inducements, monetary or otherwise, will be offered to any person to
influence their donation of human material.

ARTICLE H.5. CONTINUED BAN ON FUNDING OF HUMAN EMBRYO RESEARCH

a.    Pursuant to Public Law(s) cited in paragraph b., below, NIH is prohibited
      from using appropriated funds to support human embryo research. Contract
      funds may not be used for (1) the creation of a human embryo or embryos
      for research purposes; or (2) research in which a human embryo or embryos
      are destroyed, discarded, or knowingly subjected to risk of injury or
      death greater than that allowed for research on fetuses in utero under 45
      CFR 46.208(a)(2) and Section 498(b) of the Public Health Service Act (42
      U.S.C. 289g(b)). The term "human embryo or embryos" includes any organism,
      not protected as a human subject under 45 CFR 46 as of the date of the
      enactment of this Act, that is derived by fertilization, parthenogenesis,
      cloning, or any other means from one or more human gametes or human
      diploid cells.

      Additionally, in accordance with a March 4, 1997 Presidential Memorandum,
      Federal funds may not be used for cloning of human beings.

b.    Public Law and Section No.           Fiscal Year         Period Covered

            105-277                             99           10/01/98 - 09/30/99

ARTICLE H.6. NEEDLE EXCHANGE

a.    Pursuant to Public Law(s) cited in paragraph b., below, contract funds
      shall not be used to carry out any program of distributing sterile needles
      or syringes for the hypodermic injection of any illegal drug.

b.    Public Law and Section No.           Fiscal Year         Period Covered

            105-277                             99           10/01/98 - 09/30/99

ARTICLE H.7. INTRODUCTION OF RODENTS AND RODENT PRODUCTS

No rodent or rodent product shall be delivered into the NIH, NIAID environment
directly, or through collaborative research or holding facilities under contract
to NIAID except by permit. Direct shipments to NIH from a commercial colony will
be considered exempt. Non-exempt sources must be approved by permit issued
through the National Center for Research Resources (NCRR). The permit must be
obtained by the Contractor prior to the shipment to NIH of the rodents and/or
rodent products. The Contractor must be sure that this permit exists and is
current before transferring rodents or rodent products into the NIH, NIAID
environment. Refusal or negligence to do so will be considered a material breach
of contract and may be treated as any other such material breach. Applications
for permits should be submitted not less than 30 days prior to shipping date to:
NIH Veterinary Resources Branch (VRP), National Center for Research Resources
(NCRR), Scientific Services Branch, Laboratory Sciences Section, Building 28A,
Room 111, 28 LIBRARY DR MSC 5210, BETHESDA MD 20892-5210, (301)496-4463.

                                       15

<PAGE>

                                                       Contract No. NO1-AI-95373

ARTICLE H.8. ANIMAL WELFARE ASSURANCE

The Contractor shall obtain, prior to the start of any work under this contract,
an approved Animal Welfare Assurance from the Office of Protection from Research
Risks (OPRR), Office of the Director, NIH, as required by Section I-43-30 of the
Public Health Service Policy on Humane Care and Use of Laboratory Animals. The
Contractor shall maintain such assurance for the duration of this contract, and
any subcontractors performing work under this contract involving the use of
animals shall also obtain and maintain an approved Animal Welfare Assurance.

ARTICLE H.9. RESTRICTION FROM USE OF LIVE VERTEBRATE ANIMALS

UNDER GOVERNING POLICY, FEDERAL FUNDS ADMINISTERED BY THE PUBLIC HEALTH SERVICE
(PHS) SHALL NOT BE EXPENDED FOR RESEARCH INVOLVING LIVE VERTEBRATE ANIMALS
WITHOUT PRIOR APPROVAL BY THE OFFICE FOR PROTECTION PROM RESEARCH RISKS (OPRR)
OF AN ASSURANCE TO COMPLY WITH THE PHS POLICY ON HUMANE CARE AND USE OF
LABORATORY ANIMALS. THIS RESTRICTION APPLIES TO ALL PERFORMANCE SITES WITHOUT
OPRR-APPROVED ASSURANCES, WHETHER DOMESTIC OR FOREIGN.

ARTICLE H.1O. SALARY RATE LIMITATION LEGISLATION PROVISIONS

a.    Pursuant to Public Law(s) cited in paragraph b., below, no NIH Fiscal Year
      funds for the applicable fiscal year(s) and periods cited in paragraph b.,
      below may be used to pay the direct salary of an individual through this
      contract at a rate in excess of applicable amount shown for the fiscal
      year and period covered. Direct salary is exclusive of overhead, fringe
      benefits and general and administrative expenses. The per year salary rate
      limit also applies to individuals proposed under subcontracts. If this is
      a multi-year contract, it may be subject to unilateral modifications by
      the Government if an individual's salary rate exceeds any salary rate
      ceiling established in future DHHS appropriation acts.

                                                                Dollar Amount of
b.    Public Law No.    Fiscal Year         Period Covered     Salary Limitation

         105-277           99            10/01/98 - 09/30/99       $125,900

ARTICLE H.11. EPA ENERGY STAR REQUIREMENTS

In compliance with Executive Order 12845 (requiring Agencies to purchase energy
efficient computer equipment) all microcomputers, including personal computers,
monitors, and printers that are deliverables under the procurement or are
purchased by the contractor using Government funds in performance of a contract
shall be equipped with or meet the energy efficient low-power standby feature as
defined by the EPA Energy Star program unless the equipment always meets EPA
Energy Star efficiency levels. The microcomputer, as configured with all
components, must be Energy Star compliant.

This low-power feature must already be activated when the computer equipment is
delivered to the agency and be of equivalent functionality of similar power
managed models. If the equipment will be used on a local area network, the
vendor must provide equipment that is fully compatible with the network
environment In addition, the equipment will run commercial off-the-shelf
software both before and after recovery from its energy conservation mode.

                                       16
<PAGE>

                                                       Contract No. NO1-AI-95373

ARTICLE H.12. PUBLICATION AND PUBLICITY

The contractor shall acknowledge the support of the National Institutes of
Health whenever publicizing the work under this contract in any media by
including an acknowledgment substantially as follows:

      "This project has been funded in whole or in part with Federal funds from
      the National Institute of Allergy and Infectious Diseases, National
      Institutes of Health, under Contract No. N01-AI-95373."

ARTICLE H.13. PRESS RELEASES

a.    Pursuant to Public Law(s) cited in paragraph b., below, the contractor
      shall clearly state, when issuing statements, press releases, requests for
      proposals, bid solicitations and other documents describing projects or
      programs funded in whole or in part with Federal money: (1) the percentage
      of the total costs of the program or project which will be fInanced with
      Federal money; (2) the dollar amount of Federal funds for the project or
      program; and (3) the percentage and dollar amount of the total costs of
      the project or program that will be financed by nongovernmental sources.

b.    Public Law and Section No.          Fiscal Year        Period Covered

              105-277                         99           10/01/98 - 09/30/99

ARTICLE H.14. TASK ORDER/DELIVERY ORDER CONTRACT OMBUDSMAN

In accordance with FAR 16.505(b)(4), the following individual has been
designated as the NIH Ombudsman for task order and delivery order contracts.

      James F. O'Donnell, Ph.D, Director, Office of Extramural Programs
                         OR
      Philip S. Chen, Jr., Ph.D., Associate Director for Intramural Affairs

ARTICLE H.15. REPORTING MATTERS INVOLVING FRAUD, WASTE AND ABUSE

Anyone who becomes aware of the existence or apparent existence of fraud, waste
and abuse in NIH funded programs is encouraged to report such matters to the HHS
Inspector General's Office in writing or on the Inspector General's Hotline. The
toll free number is 1-800-HHS-TIPS (1-800-447-8477). All telephone calls will be
handled confidentially. The e-mai1 address is Htips@os.dhhs.gov and the mailing
address is:

            Office of Inspector General
            Department of Health and Human Services
            TIPS HOTLINE
            P.O. Box 23489
            Washington, D.C. 20026

Information regarding procedural matters is contained in the NIH Manual Chapter
1754, which is available on (http://www1.od.nih.gov/oma/oma.htm)

                                       17

<PAGE>

                                                       Contract No. NO1-AI-95373

ARTICLE 11.16. YEAR 2000 COMPLIANCE

In accordance with FAR 39.106, Information Technology acquired under this
contract must be Year 2000 compliant as set forth in the following clause(s):

1.    Service Involving the Use of Information Technology

      YEAR 2000 COMPLIANCE--SERVICE INVOLVING THE USE OF INFORMATION TECHNOLOGY

      The Contractor agrees that each item of hardware, software, and firmware
      used under this contract shall be able to accurately process date data
      (including, but not limited to, calculating, comparing and sequencing)
      from, into and between the twentieth and twenty-first centuries and the
      Year 1999 and the Year 2000 and leap year calculations.

                                (End of Clause)

2.    Noncommercial Supply Items Warranty

      YEAR 2000 WARRANTY--NONCOMMERCIAL SUPPLY ITEMS

      The contractor warrants that each noncommercial item of hardware,
      software, and firmware delivered or developed under this contract and
      listed below shall be able to accurately process date data (including, but
      not limited to, calculating, comparing and sequencing) from, into and
      between the twentieth and twenty-first centuries and the Year 1999 and the
      Year 2000 and leap year calculations, when used in accordance with the
      item documentation provided by the contractor, provided that all listed or
      unlisted items (e.g., hardware, software and firmware) used in combination
      with such listed item properly exchange date data with it. If the contract
      requires that specific listed items must perform as a system in accordance
      with the foregoing warranty, then that warranty shall apply to those
      listed items as a system. The duration of this warranty and the remedies
      available to the Government for breach of this warranty shall be as
      defined in, and subject to, the terms and limitations of any general
      warranty provisions of this contract provided that notwithstanding any
      provision to the contrary in such warranty provision(s), or in the absence
      of any such warranty provision(s), the remedies, available to the
      Government under this warranty shall include repair or replacement of any
      listed item whose noncompliance is discovered and made known to the
      contractor in writing within ninety (90) days after acceptance. Nothing in
      this warranty shall be construed to limit any rights or remedies the
      Government may otherwise have under this contract with respect to defects
      other than Year 2000 performance.

                  YEAR 2000 COMPLIANT ITEMS
                  All hardware and software items used to manipulate data under
                  this contract
                  --------------------------------------------------------------

                  --------------------------------------------------------------
                          (end of clause)

                                       18

<PAGE>

                                                       Contract No. NO1-AI-95373

3.    Commercial Supply Products Warranty

      YEAR 2000 WARRANTY--COMMERCIAL SUPPLY ITEMS

      The contractor warrants that each hardware, software and firmware product
      delivered under this contract and listed below shall be able to accurately
      process date data (including, but not limited to, calculating, comparing,
      and sequencing) from, into, and between the twentieth and twenty-first
      centuries and the Year 1999 and the Year 2000 and leap year calculations,
      when used in accordance with the product documentation provided by the
      contractor, provided that all listed or unlisted products (e.g., hardware,
      software, firmware) used in combination with such listed product properly
      exchange date data with it. If the contract requires that specific listed
      products must perform as a system in accordance with the foregoing
      warranty, then that warranty shall apply to those listed products as a
      system. The duration of this warranty and the remedies available to the
      Government for breach of this warranty shall be as defined in, and subject
      to, the terms and limitations of the contractor's standard commercial
      warranty or warranties contained in this contract, provided that
      notwithstanding any provision to the contrary in such commercial warranty
      or warranties, the remedies available to the Government under this
      warranty shall include repair or replacement of any listed product whose
      non-compliance is discovered and made known to the contractor in writing
      within ninety (90) days after acceptance. Nothing in this warranty shall
      be construed to limit any rights or remedies the Government may otherwise
      have under this contract with respect to defects other than Year 2000
      performance.

                  YEAR 2000 COMPLIANT ITEMS

                  All hardware and software items used to manipulate data under
                  this contract

                  --------------------------------------------------------------

                  --------------------------------------------------------------
                          (end of clause)

                                       19
<PAGE>

                                                       Contract No. NO1-AI-95373

                           PART II - CONTRACT CLAUSES

SECTION I - CONTRACT CLAUSES

                                       20

<PAGE>

                                                       Contract No. NO1-AI-95373

ARTICLE I.1. GENERAL CLAUSES FOR A COST-REIMBURSEMENT RESEARCH AND
DEVELOPMENT CONTRACT - FAR 52.252-2, CLAUSES INCORPORATED BY REFERENCE
(FEBRUARY 1998)

This contract incorporates the following clauses by reference, with the same
force and effect as if they were given in full text. Upon request, the
Contracting Officer will make their full text available. Also, the full text of
a clause may be accessed electronically at this address:
http://www.arnet.gov/far/.

a.    FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES:

   FAR
CLAUSE NO.       DATE      TITLE
----------       ----      -----

 52.202-1       Oct 1995   Definitions

 52.203-3       Apr 1984   Gratuities (Over $100,000)

 52.203-5       Apr 1984   Covenant Against Contingent Fees (Over $100,000)

 52.203-6       Jul 1995   Restrictions on Subcontractor Sales to the Government
                           (Over $100,000)

 52.203-7       Jul 1995   Anti-Kickback Procedures(Over $100,000)

 52.203-8       Jan 1997   Cancellation, Rescission, and Recovery of Funds for
                           Illegal or Improper Activity (Over $100,000)

 52.203-10      Jan 1997   Price or Fee Adjustment for Illegal or Improper
                           Activity (Over $100,000)

 52.203-12      Jun 1997   Limitation on Payments to Influence Certain Federal
                           Transactions (Over $100,000)

 52.204-4       Jun 1996   Printing or Copying Double-Sided on Recycled Paper
                           (Over $100,000)

 52.209-6       Jul 1995   Protecting the Government's Interests When
                           Subcontracting With Contractors Debarred, Suspended,
                           or Proposed for Debarment (Over $25,000)

 52.215-2       Aug 1996   Audit and Records - Negotiation (Over $100,000)

 52.215-8       Oct 1997   Order of Precedence - Uniform Contract Format

 52.215-10      Oct 1997   Price Reduction for Defective Cost or Pricing Data

 52.215-12      Oct 1997   Subcontractor Cost or Pricing Data (Over $500,000)

 52.215-14      Oct 1997   Integrity of Unit Prices (Over $100,000)

 52.215-15      Dec 1998   Pension Adjustments and Asset Reversions

 52.215-18      Oct 1997   Reversion or Adjustment of Plans for Post-Retirement
                           Benefits (PRB) other than Pensions

 52.215-19      Oct 1997   Notification of Ownership Changes

 52.215-21      Oct 1997   Requirements for Cost or Pricing Data or Information
                           Other Than Cost or Pricing Data - Modifications

 52.216-7       Apr 1998   Allowable Cost and Payment

                                       21
<PAGE>

                                                       Contract No. NO1-AI-95373

 52.216-8       Mar 1997   Fixed Fee

 52.219-8       Jan 1999   Utilization of Small Business Concerns (Over
                           $100,000)

 52.219-9       Jan 1999   Small Business Subcontracting Plan (Over $500,000)

 52.219-16      Jan 1999   Liquidated Damages - Subcontracting Plan (Over
                           $500,000)

 52.222-2       Jul 1990   Payment for Overtime Premium (Over $100,000) (Note:
                           The dollar amount in paragraph (a) of this clause is
                           $0 unless otherwise specified in the contract.)

 52.222-3       Aug 1996   Convict Labor

 52.222-24      Feb 1999   Preaward On-Site Equal Opportunity Compliance
                           Evaluation

 52.222-26      Feb 1999   Equal Opportunity

 52.222-35      Apr 1998   Affirmative Action for Disabled Veterans and Veterans
                           of the Veitnam Era

 52.222-36      Jun 1998   Affirmative Action for Workers with Disabilities

 52.222-37      Jan 1999   Employment Reports on Disabled Veterans and
                           Veterans of the Vietnam Era

 52.223-2       Apr 1984   Clean Air and Water (Over $100,000)

 52.223-6       Jan 1997   Drug-Free Workplace

 52.223-14      Oct 1996   Toxic Chemical Release Reporting

 52.225-3       Jan 1994   Buy American Act - Supplies

 52.225-11      Aug 1998   Restrictions on Certain Foreign Purchases

 52.227-1       Jul 1995   Authorization and Consent, Alternate I (Apr 1984)

 52.227-2       Aug 1996   Notice and Assistance Regarding Patent and Copyright
                           Infringement (Over $100,000)

 52.227-11      Jun 1997   Patent Rights - Retention by the Contractor (Short
                           Form) (Note: In accordance with FAR 27.303(a)(2),
                           paragraph (f) is modified to include the requirements
                           in FAR 27.303(a)(2)(i) through (iv). The frequency of
                           reporting in (i) is annual.

 52.227-14      Jun 1987   Rights in Data - General

 52.232-9       Apr 1984   Limitation on Withholding of Payments

 52.232-17      Jun 1996   Interest (Over $100,000)

 52.232-20      Apr 1984   Limitation of Cost

 52.232-23      Jan 1986   Assignment of Claims

 52.232-25      Jun 1997   Prompt Payment

 52.232-33      May 1999   Payment by Electronic Funds Transfer--Central
                           Contractor Registration

 52.233-1       Dec 1998   Disputes

                                       22

<PAGE>

                                                       Contract No. NO1-AI-95373

 52.233-3       Aug 1996   Protest After Award, Alternate I (Jun 1985)

 52.242-1       Apr 1984   Notice of Intent to Disallow Costs

 52.242-3       Oct 1995   Penalties for Unallowable Costs (Over $500,000)

 52.242-4       Jan 1997   Certification of Final Indirect Costs

 52.242-13      Jul 1995   Bankruptcy (Over $100,000)

 52.243-2       Aug 1987   Changes - Cost Reimbursement, Alternate V (Apr 1984)

 52.243-7       Apr 1984   Notification of Changes

 52.244-2       Aug 1998   Subcontracts, Alternate II (Aug 1998) *If written
                           consent to subcontract is required, the identified
                           subcontracts are listed in ARTICLE B, Advance
                           Understandings.

 52.244-5       Dec 1996   Competition in Subcontracting (Over $100,000)

 52.245-5       Jan 1986   Government Property (Cost-Reimbursement, Time and
                           Material, or Labor-Hour Contract)

 52.246-23      Feb 1997   Limitation of Liability (Over $100,000)

 52.249-6       Sep 1996   Termination (Cost-Reimbursement)

 52.249-14      Apr 1984   Excusable Delays

 52.253-1       Jan 1991   Computer Generated Forms

b.    DEPARTMENT OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION (HHSAR) (48
      CFR CHAPTER 3) CLAUSES:

   HHSAR
 CLAUSE NO.         DATE     TITLE
 ----------         ----     -----

 352.202-1        Apr 1984   Definitions - Alternate I (Apr 1984)

 352.228-7        Dec 1991   Insurance - Liability to Third Persons

 352.232-9        Apr 1984   Withholding of Contract Payments

 352.233-70       Apr 1984   Litigation and Claims

 352.242-71       Apr 1984   Final Decisions on Audit Findings

 352.270-5        Apr 1984   Key Personnel

 352.270-6        Jul 1991   Publication and Publicity

 352.270-7        Apr 1984   Paperwork Reduction Act

[End of GENERAL CLAUSES FOR A COST-REIMBURSEMENT RESEARCH AND DEVELOPMENT
CONTRACT - Rev. 5/1999].

                                       23
<PAGE>

                                                       Contract No. NO1-AI-95373

ARTICLE I.2  AUTHORIZED SUBSTITUTION OF CLAUSES

ARTICLE I.1. of this SECTION is hereby modified as follows:

FAR Clause 52.232-20, LIMITATION OF COST, is deleted in its entirety and FAR
Clause 52.232-22, LIMITATION OF FUNDS (APRIL 1984) is substituted therefor.

ARTICLE I.3. ADDITIONAL CONTRACT CLAUSES

This contract incorporates the following clauses by reference, with the same
force and effect, as if they were given in full text. Upon request, the
contracting officer will make their full text available.

a.    FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES

      (1)   FAR 52.215-17, Waiver of Facilities Capital Cost of Money (OCTOBER
            1997).

      (2)   FAR 52.216-15, Predetermined Indirect Cost Rates (APRIL 1998).

      (3)   FAR 52.216-18, Ordering (OCTOBER 1995). Such orders may be issued
            from the effective date of this contract through the expiration date
            of this contract.

      (4)   FAR 52.216-22, Indefinite Quantity (OCTOBER 1995). The Contractor
            shall not be required to make any deliveries under this contract
            after the expiration date of the contract.

      (5)   FAR 52.219.4, Notice of Price Evaluation Preference for HUBZone
            Small Business Concerns (JANUARY 1999).

            "(c)  Waiver of evaluation preference.....

                  |_|   Offeror elects to waive the evaluation preference."

      (6)   FAR 52.219-14, Limitation of Subcontracting (DECEMBER 1996).

      (7)   FAR 52.219-25, Small Disadvantaged Business Participation Program--
            Disadvantaged Status and Reporting (JANUARY 1999).

      (8)   FAR 52.227-14, Rights in Data - General (JUNE 1987).

      (9)   Alternate IV (JUNE 1987), FAR 52.227-14, Rights in Data - General
            (JUNE 1987).

      (10)  FAR 52.243.2, Changes--Cost Reimbursement (AUGUST 1987), Alternate V
            (APRIL 1984.)

b.    DEPARTMENT OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION/PUBLIC
      HEALTH SERVICE ACQUISITION REGULATION (HHSAR)/(PHSAR)(48 CHAPTER 3)
      CLAUSES:

      (1)   PHS 352.223-70, Safety and Health (Deviation) (AUGUST 1997).

      (2)   HHSAR 352.224-70, Confidentiality of Information (APRIL 1984).

      (3)   PHS 352.280-1b, Protection of Human Subjects (OCTOBER 1986).

                                       24
<PAGE>

                                                       Contract No. NO1-AI-95373

c.    NATIONAL INSTITUTES OF HEALTH (NIH) RESEARCH CONTRACTING (RC) CLAUSES:

      The following clauses are attached and made a part of this contract:

      1.    NIH (RC)-7, Procurement of Certain Equipment (APRIL 1984) (OMB
            Bulletin 81-16).

ARTICLE I.4. ADDITIONAL FAR CONTRACT CLAUSES INCLUDED IN FULL TEXT

This contract incorporates the following clauses in full text.

FEDERAL ACQUISITION REGULATION (FAR)(48 CFR CHAPTER 1) CLAUSES:

FAR Clause 52.244-6, SUBCONTRACTS FOR COMMERCIAL ITEMS AND COMMERCIAL COMPONENTS
(OCTOBER 1998)

      (a)   Definition.

            Commercial item, as used in this clause, has the meaning contained
            in the clause at 52.202-1, Definitions.

            Subcontract, as used in this clause, includes a transfer of
            commercial items between divisions, subsidiaries, or affiliates of
            the Contractor or subcontractor at any tier.

      (b)   To the maximum extent practicable, the Contractor shall incorporate,
            and require its subcontractors at all tiers to incorporate,
            commercial items or nondevelopmental items as components of items to
            be supplied under this contract.

      (c)   Notwithstanding any offer clause of this contract, the Contractor is
            not required to include and FAR provision or clause, other than
            those listed below to the extent they are applicable and as may be
            required to establish the responableness of prices under Part 15, in
            a subcontract at any tier for commercial items or commercial
            components:

                  (1)   52.222-26, Equal Opportunity (E.O. 11246);

                  (2)   52.222-35, Affirmative Action for Disabled Veterans and
                        Veterans of the Vietnam Era (38 U.S.C. 4212(a));

                  (3)   52.222-36, Affirmative Action for Workers with
                        Disabilities (29 U.S.C. 793); and

                  (4)   52.247-64, Preference for Privately Owned U.S.-Flagged
                        Commercial Vessels (46 U.S.C. 1241) (flow down not
                        required for subcontracts awarded beginning May 1,
                        1996).

      (d)   The Contractor shall include the terms of this clause, including
            this paragraph (d), in subcontracts awarded under this contract.

                                       25
<PAGE>

                                                       Contract No. NO1-AI-95373

                                    PART III

SECTION J - LIST OF ATTACHMENTS

The following documents are attached and incorporated in this contract:

1.    Statement of Work, July 9, 4 pages.

2.    Invoice/Financing Request Instructions for NIH Cost-Reimbursement Type
      Contracts, NIH(RC)-1, (5/97), 4 pages.

3.    Safety and Health (Deviation), PHSAR Clause 352.223-70, (8/97), 1 page.

4.    Procurement of Certain Equipment, NIH(RC)-7, 4/1/84, 1 page.

                                       26
<PAGE>

                                                       Contract No. NO1-AI-95373

                                     PART IV

SECTION K - REPRESENTATIONS AND CERTIFICATIONS

The following documents are incorporated by reference in this contract:

1.    Representations and Certifications, dated May 13, 1999.

                               END of the SCHEDULE
                                   (CONTRACT)

                                       27
<PAGE>

                                                       Contract No. N01-AI-95373

                                STATEMENT OF WORK

                                                                    ATTACHMENT A

                                   BACKGROUND

The development of a vaccine to prevent the spread of HIV infection has been
identified by the NIAID as a goal of the highest priority. While advances in
immunology and molecular biology continue to offer an ever expanding array of
approaches to the development of new candidates, the limited capacity to move
promising concepts through the development process presents a substantial
barrier to the full achievement of this potential. Limited industry involvement
in key areas, especially international (non-clade B) vaccines, calls for a
non-traditional, more active and developmentally oriented response by NIH and
NIAID to meet the public health threat of the AIDS epidemic. Resources that
could rapidly and efficiently close development and production gaps would
greatly enhance the capacity to respond to emerging needs identified by NIAID
and its advisory groups. The HIV Vaccine Production Contract will support
applied research that is not adequately being pursued by industry and will
further develop leads derived from investigator-initiated research.

                                   INTRODUCTION

The objective of the Contract is to provide to the NIAID with a full range of
developmental resources to bring an HIV vaccine concept from the laboratory to
initial human testing. It is envisioned that the ability to encourage and to
support the development of multiple approaches will result in a shared knowledge
base from which the best vaccine prototypes will emerge.

                                   STATEMENT OF WORK

WORK STATEMENT for the HIV Vaccine Production Contract.

Independently, and not as an agent of the Government, the Contractor shall
furnish all the necessary services, qualified personnel, materials, equipment,
and facilities, not otherwise provided by the Government under the terms of the
contract, directly or through subcontractors and/or consultants, as needed to
undertake targeted research essential to translating basic research concepts
into prototype vaccine products, under the direction of NIAID staff and as
commended by existing and ad hoc NIAID advisory groups.

Statement of Work                                                  ATTACHMENT 1
(07/09/99)                           1                                    Page 1

<PAGE>
                                                       Contract No. NO1-AI-95373

Specifically, the Contractor shall:

PART A: VACCINE PRODUCTION

1. Produce, scale-up, characterize and formulate specific vaccine antigens
   and reagents as directed by the Project Officer via a Task Order issued by
   the NIAID, Produce pilot lots of candidate vaccines under GLP/cGMP
   appropriate for Phase I and Phase II human clinical trials, at the
   direction of the Project Officer in one or more of the following vaccine
   Categories:

      (a)   Synthetic peptides--Clinical grade purified HIV peptide vaccines.

      (b)   Recombinant subunits--Clinical grade purified subunit vaccines.

      (c)   Plasmid DNA vaccines--Clinical grade recombinant plasmid DNA with
            sequence(s) of genes relevant to AIDS vaccines.

      (d)   Vector based vaccines--Clinical grade recombinant vaccines
            containing relevant genes (eg. vaccinia, avipox, adenovirus, polio,
            BCG, Salmonella, etc.).

      (e)   Whole killed/Virus-like Particle - Clinical grade nonviable HIV-1
            virus vaccine.

      (f)   Live attenuated virus--Attenuated HIV-1 virus vaccine.

2. Develop and manufacture specific vaccine products.

      a)    Consult and coordinate with the product inventor throughout the
            development process. Complete a material transfer agreement, if
            needed.

      b)    Develop detailed production plan and budgets for manufacture of lots
            of candidate vaccine products prior to undertaking GLP/cGMP
            production.

      c)    Assure that facilities and all planned procedures meet FDA standards
            and requirements prior to GLP/cGMP production. -

      d)    Prepare, where applicable, master stocks, cell banks, bacterial or
            viral clones, etc.

      e)    Purchase, where applicable, products and materials necessary for
            vaccine production.

Statement of Work                                                   ATTACHMENT 1
(07/09/99)                           2                                    Page 2

<PAGE>
                                                       Contract No. NO1-AI-95373

      f)    Optimize expression in systems suitable for vaccine production and
            scale-up production to required capacity.

      g)    Maintain an inventory of test and pilot lots of vaccine candidates
            that have been produced. Periodically, as required, examine titer or
            potency of vaccine products.

      h)    Produce reagents necessary for the testing or evaluation of immune
            responses to vaccine products.

      i)    Ship the manufactured, packaged, and labeled dosage forms utilizing
            shipping procedures and materials to maximize product stability.

      j)    Manage and account for intellectual property rights that pre-exist
            or may develop through the activities of the Contractor, including
            maintenance of security of confidential and/or proprietary data.

3. Provide facilities, equipment and resources:

      a)    Receive, store and manipulate biohazardous materials (Biosafety
            Level 2 and 3 Containment as required) and maintain their viability
            in facilities which provide aseptic and/or sterile conditions as
            appropriate.

      b)    Maintain and operate controlled storage of samples at appropriate
            temperatures with appropriate monitoring for failure (Room
            temperature through -90 (degree) C. liquid nitrogen storage may be
            required for some products).

      e)    Provide facilities and equipment suitable for GLP/cGMP production of
            vaccine products.

      d)    Provide protective garments, equipment and sufficient monitoring to
            assure safe handling of potentially hazardous materials, including
            radioactive materials, for the safety and protection of workers.

      e)    Conduct work under the contract in accordance with all applicable
            and current Federal, state, and local laws, codes, ordinances and
            regulations, as well as all PHS Safety and Health provisions)

4. Perform vaccine lot characterization tests.

At various steps during the manufacture of a vaccine the product must be
characterized. Prior to use of a vaccine in clinical studies the manufactured
vaccine will need to undergo final lot release testing. As described in the
regulations for General Biological Product Standards (21 CFR 610) the following
tests must be performed for each lot of vaccine.

Statement of Work                                                   ATTACHMENT 1
(07/09/99)                           3                                    Page 3

<PAGE>
                                                       Contract No. NO1-AI-95373

      a)    Test for Potency. A test for potency (21 CFR 610.10) will evaluate
            in an in vitro or in vivo test the specific ability of the vaccine
            to effect a given response, such as an immune response in mice,
            which should be supportive of the efficacy of the vaccine in humans.
            In the case of DNA vaccines potency maybe evidenced by the
            production of the pertinent antigen in a transfected cell line.

       b)   Test for General Safety. The general safety test (21 CFR 610.11)
            must be performed in mice and guinea pigs on each lot of vaccine to
            detect extraneous toxic contaminants potentially introduced during
            manufacture.

      c)    Test for Sterility. A test for sterility (21 CFR 610.12) must be
            performed as described in the regulations.

      d)    Test for Purity. A test for purity (21 CFR 610.13) must be performed
            on each lot to ensure that the product is free from extraneous
            material except for that which is unavoidable due to the
            manufacturing process. In addition, the test for purity includes an
            evaluation of residual moisture and the presence of pyrogenic
            substances in the product.

      e)    Test for Identity. The test for identity (21 CFR 601.14) is
            generally a physical or chemical test performed to establish the
            identity of the material in the final container.

      f)    Test for Quantity. A measure of the amount of material present is
            imperative for calculating the dilution of the bulk material
            required for the final container fill.

      g)    All other tests as may be required for specific vaccine types.

5. Perform stability testing.

6. Participate in discussions with the FDA during pre-IND and IND meetings.

7. Ensure an orderly transition to a successor Contractor.

   Six months before the end of the awarded Contract, the Contractor shall
   define and implement an orderly transition of data, specimens and products
   to any successor Contractor or to the Government, subject to Project
   Officer direction, and shall deliver, if requested by the Project Officer
   and by the completion date of the Contract, the following items: original
   data, reagents, stored specimens (and any necessary information related
   thereto), Government-owned equipment and property.

8. Meet with the Project Officer at periodic intervals, to be scheduled after
   contract award.

9. Retain all records, samples, histopathological slides, etc. as indicated
   under GLP and cGMP guidelines and be able to make them available.

Statement of Work                                                   ATTACHMENT 1
(07/09/99)                           4                                    Page 4

<PAGE>
                                                       Contract No. NO1-AI-95373

                     INVOICE/FINANCING REQUEST INSTRUCTIONS
              FOR NIH COST-REIMBURSEMENT TYPE CONTRACTS, NIH(RC)-1

General: The contractor shall submit claims for reimbursement in the manner and
format described herein and as illustrated in the sample invoice/financing
request.

Format: Standard Form 1034, "Public Voucher for Purchases and Services Other
Than Personal," and Standard Form 1035, "Public Voucher for Purchases and
Services Other Than Personal--Continuation Sheet," or reproduced copies of such
forms marked ORIGINAL should be used to submit claims for reimbursement. In lieu
of SF-1034 and SF-1O35, claims maybe submitted on the payee's letter-head or
self-designed form provided that it contains the information shown on the sample
invoice/financing request.

Number of Copies: As indicated In the invoice Submission Clause in the contract.

Frequency: Invoices/financing requests submitted in accordance with the Payment
Clause shall be submitted monthly less otherwise authorized by the contracting
officer.

Cost Incurrence Period: Costs incurred must be within the contract performance
period or covered by precontract cost provisions.

Billing of Costs Incurred: If billed costs include: (1) costs of a prior
billing period, but not previously billed; or (2) costs incurred during the
contract period and claimed after the contract period has expired, the
amount and month(s) which such costs were incurred shall be cited.

Contractor's Fiscal Year: Invoices/financing requests shall be prepared in such
a manner that costs claimed can be identified with the contractor's fiscal year.

Currency: All NIH contracts are expressed in United States dollars. When
payments are made in a currency other in United States dollars, billings on the
contract shall be expressed, and payment by the United States Government shall
be made, in that other currency at amounts coincident with actual costs
incurred. Currency fluctuations may not be a basis of gain or loss to the
contractor. Notwithstanding the above, the total of all invoices paid under this
contract may not exceed the United States dollars authorized.

Costs Requiring Prior Approval: Costs requiring the contracting officer's
approval, which are not set forth in an Advance Understanding in the contract
shall be so identified and reference the Contracting Officer's Authorization
(COA) Number. In addition, any cost set forth in an Advance Understanding shall
be shown as a separate line item the request.

Invoice/Financing Request Identification: Each invoice/financing request shall
be identified as either:

(a)   Interim Invoice/Contract Financing Request - These are interim payment
      requests submitted during the contract performance period.

(b)   Completion Invoice--The completion invoice is submitted promptly upon
      completion of the work; but no later than one year from the contract
      completion date, or within 120 days after settlement of the final indirect
      cost rates covering the year in which this contract is physically complete
      (whichever date is later). The completion invoice should be submitted when
      all costs have been assigned to the contract and all performance
      provisions have been completed.

(c)   Final Invoice--A final invoice may be required after the amounts owed
      have been settled between the Government and the contractor (e.g.,
      resolution of all suspensions and audit exceptions).

Preparation and Itemization of the Invoice/Financing Request: The contractor
shall furnish the information set forth the explanatory notes below. These notes
are keyed to the entries on the sample invoice/financing request.

NIH(RC)-1                                                           ATTACHMENT 2
Rev. 5/97                                                                 Page 1

<PAGE>
                                                       Contract No. NO1-AI-95373

(a)   Designated Billing Office Name and Address--Enter the designated billing
      office name and address, identified in the Invoice Submission Clause of
      the contract, on all copies of the invoice/financing request.

(b)   Invoice/Financing Request Number--Insert the appropriate serial number
      of the invoice/financing request.

(c)   Date Invoice/Financing Request Prepared--Insert the date the
      invoice/financing request is prepared.

(d)   Contract Number and Date--Insert the contract number and the effective
      date of the contract,

(e)   Payee's Name and Address--Show the contractor's name (as it appears in
      the contract), correct address, and the title and phone number of the
      responsible official to whom payment is to be sent, When an approved
      assignment has been made by the contractor, or a different payee has been
      designated, then insert the name and address of the payee instead of the
      contractor.

(f)   Total Estimated Cost of Contract--Insert the total estimated cost of
      the contract, exclusive of fixed-fee. For incrementally funded contracts,
      enter the amount currently obligated and available for payment.

(g)   Total Fixed-Fee--Insert the total fixed-fee (where applicable). For
      incrementally funded contracts, enter the amount currently obligated and
      available for payment.

(h)   Billing Period--Insert the beginning and ending dates (month, day, and
      year) of the period in which costs were incurred and for which
      reimbursement is claimed.

(i)   Amount Billed for Current Period--Insert the amount billed for the
      major cost elements, adjustments, and adjusted amounts for the period.

(j)   Cumulative Amount from Inception--Insert the cumulative amounts billed
      for the major cost elements and adjusted amounts claimed during this
      contract.

(k)   Direct Costs--Insert the major cost elements. For each element, consider
      the application of the paragraph entitled "Costs Requiring Prior Approval"
      on page 1 of these instructions.

      (1)   Direct Labor--Include salaries and wages paid (or accrued) for
            direct performance of the contract.

      (2)   Fringe Benefits--List any fringe benefits applicable to direct labor
            and billed as a direct cost. Fringe benefits included in indirect
            costs should not be identified here.

      (3)   Accountable Personal Property--Include permanent research equipment
            and general purpose equipment having a unit acquisition cost of
            $1,000 or more and having an expected service life of more than two
            years, and sensitive property regardless of cost (see the DHHS
            Contractor's Guide for Control of Government Property). Show
            permanent research equipment separate from general purpose
            equipment. Prepare and attach Form HHS--565, "Report of Accountable
            Property," in accordance with the following instructions:

            List each item for which reimbursement is requested. A reference
            shall be made to the following (as applicable):

            -     The item number for the specific piece of equipment listed in
                  the Property Schedule.

            -     The COA letter and number, if the equipment is not covered by
                  the Property Schedule.

            -     Be preceded by an asterisk (*) if the equipment is below the
                  approval level.

            Further itemization of invoices/financing requests shall only be
            required for items having specific limitations set forth in the
            contract.

NIH(RC)-1                                                           ATTACHMENT 2
Rev. 5/97                                                                 Page 2

<PAGE>
                                                       Contract No. NO1-AI-95373

      (4)   Materials and Supplies--Include equipment with unit costs of less
            than $1,000 or an expected service life of two years or less, and
            consumable material and supplies regardless of amount.

      (5)   Premium Pay--List remuneration in excess of the basic hourly rate.

      (6)   Consultant Fee--List fees paid to consultants. Identify consultant
            by name or category as set forth in the contract's advance
            understanding or in the COA letter, as well as the effort (i.e.,
            number of hours, days, etc.) and rate being billed.

      (7)   Travel--Include domestic and foreign travel. Foreign travel is
            travel outside of Canada, the United States and its territories and
            possessions. However, for an organization located outside Canada,
            the United States and its territories and possessions, foreign
            travel means travel outside that country. Foreign travel must be
            billed separately from domestic travel.

      (8)   Subcontract Costs--List subcontractor(s) by name and amount billed.

      (9)   Other--List all other direct costs in total unless exceeding $1,000
            in amount. If over $1,000, list cost elements and dollar amounts
            separately. If the contract contains restrictions on any cost
            element, that cost element must be listed separately.

(l)   Cost of Money (COM)--Cite the COM factor and base in effect during the
      time the cost was incurred and for which reimbursement is claimed.

(m)   Indirect Costs--Overhead--Identify the cost base, indirect cost rate, and
      amount billed for each indirect cost category.

(n)   Fixed-Fee Earned--Cite the formula or method of computation for the
      fixed-fee (if any). The fixed-fee must be claimed as provided for by the
      contract.

(o)   Total Amounts Claimed--Insert the total amounts claimed for the current
      and cumulative periods.

(p)   Adjustments--Include amounts conceded by the contractor, outstanding
      suspensions, and/or disapprovals subject to appeal.

(q)   Grand Totals

The contracting officer may require the contractor to submit detailed support
for costs claimed on one or more interim invoices/financing requests.

NIH(RC)-1                                                           ATTACHMENT 2
Rev. 5/97                                                                 Page 3

<PAGE>

                                                       Contract No. NO1-AI-95373

                        SAMPLE INVOICE/FINANCING REQUEST

(a)   Billing Office Name and Address     (b)   Invoice/Financing Request No.

                                                --------------------------------

      NATIONAL INSTITUTES OF HEALTH       (c)   Date Invoice Prepared
      NIAID, CMB
      Rockledge Drive, room 2230                --------------------------------
      6700-B Rockledge Drive, MSC 7612
      Bethesda, MD 20892-7612             (d)   Contract No. and Effective Date

                                                --------------------------------
(e)   Payee's Name and Address
                                          (f)   Total Estimated Cost of Contract
      ABC CORPORATION
      100 Main Street                           --------------------------------
      Anywhere, U.S.A. zip code
                                          (g)   Total Fixed Fee

                                                --------------------------------
Attention:  Name, Title, and Phone Number
            of Official to Whom Payment is
            Sent

--------------------------------------------------------------------------------

(h)   This invoice/financing request represents reimbursable costs from Aug. 1,
      1982 through Aug. 31, 1982
--------------------------------------------------------------------------------

(i) Amount Billed

(j) Cumulative Amount

                                            for Current Period    From Inception
                                            ------------------    --------------

(k)   Direct Costs
      (1)   Direct Labor                      $  3,400              $  6,800
      (2)   Fringe Benefits                        600                 1,200
      (3)   Accountable Personal Property
            (Attach Form HHS-565)
            Permanent Research                   3,000                 6,000
            General Purpose                      2,000                 2,000
      (4)   Materials and Supplies               2,000                 4,000
      (5)   Premium Pay                            100                   150
      (6)   Consultant Fee-Dr. Jones 1 day
            @ 100 (COA #3)                         100                   100
      (7)   Travel (Domestic)                      200                   200
                   (Foreign)                       200                   200
      (8)   Subcontract Costs                      -0-                   -0-
      (9)   Other                                  -0-                   -0-
                                               -------               -------
            Total Direct Costs                 $11,600               $20,650

(l)   Cost of Money (Factor) of
      (Appropriate Base)                         2,400                 3,600
(m)   Indirect Costs--Overhead
      ___% of Direct Labor or Other Base
      (Formula)                                  4,000                 6,000
(n)   Fixed-Fee Earned (Formula)                   700                 1,400
                                               -------               -------
(o)   Total Amount Claimed                     $18,700               $31,650
(p)   Adjustments
             Outstanding Suspensions                                  (1,700)
                                                                     -------
(q)   Grand Totals                             $18,700               $29,950

"I certify that all payments requested are for appropriate purposes and in
accordance with the contract."

      ----------------------------      ----------------------------------------
      (Name of Official)                                (Title)

NIH(RC)-1                                                           ATTACHMENT 2
Rev. 5/97                                                                 Page 4

<PAGE>

                                                       Contract No. NO1-AI-95373

PHS 352.223-70 SAFETY AND HEALTH (DEVIATION) (AUGUST 1997)

(a)   To help ensure the protection of the life and health of all persons, and
      to help prevent damage to property, the Contractor shall comply with all
      Federal, State and local laws and regulations applicable to the work being
      performed under this contract. These laws are implemented and/or enforced
      by the Environmental Protection Agency, Occupational Safety and Health
      Administration and other agencies at the Federal, State and local levels
      (Federal, State and local regulatory/enforcement agencies).

(b)   Further, the Contractor shall take or cause to be taken additional safety
      measures as the Contracting Officer in conjunction with the project or
      other appropriate officer, determines to be reasonably necessary. If
      compliance with these additional safety measures results in an increase or
      decrease in the cost or time required for performance of any part of work
      under this contract, an equitable adjustment will be made in accordance
      with the applicable "Changes" Clause set forth in this contract.

(c)   The Contractor shall maintain an accurate record of, and promptly report
      to the Contracting Officer, all accidents or incidents resulting in the
      exposure of persons to toxic substances, hazardous materials or hazardous
      operations; the injury or death of any person; and/or damage to property
      incidental to work performed under the contract and all violations for
      which the Contractor has been cited by any Federal, State or local
      regulatory/enforcement agency. The report shall include a copy of the
      notice of violation and the findings of any inquiry or inspection, and an
      analysis addressing the impact these violations may have on the work
      remaining to be performed. The report shall also state the required
      action(s), if any, to be taken to correct any violation(s) noted by the
      Federal, State or local regulatory/enforcement agency and the time frame
      allowed by the agency to accomplish the necessary corrective action.

(d)   If the Contractor fails or refuses to comply promptly with the Federal,
      State or local regulatory/enforcement agency's directive(s) regarding any
      violation(s) and prescribed corrective action(s), the Contracting Officer
      may issue an order stopping all or part of the work until satisfactory
      corrective action (as approved by the Federal, State or local
      regulatory/enforcement agencies) has been taken and documented to the
      Contracting Officer. No part of the time lost due to any stop work order
      shall be subject to a claim for extension of time or costs or damages by
      the Contractor.

(e)   The Contractor shall insert the substance of this clause in each
      subcontract involving toxic substances, hazardous materials, or
      operations. Compliance with the provisions of this clause by
      subcontractors will be the responsibility of the Contractor.

                                 (End of clause)

Safety and Health Clause (Deviation)                                ATTACHMENT 3
PHS 352.223-70, (8/97)

<PAGE>

                                                       Contract No. NO1-AI-95373

PROCUREMENT OF CERTAIN EQUIPMENT

Notwithstanding any other clause in this contract, the Contractor will not be
reimbursed for the purchase, lease, or rental of any item of equipment listed in
the following Federal Supply Groups, regardless of the dollar value, without the
prior written approval of the Contracting Officer.

      67 - Photographic Equipment

      69 - Training Aids and Devices

      70 - General Purpose ADP Equipment, Software, Supplies and Support
           (Excluding 7045-ADP Supplies and Support Equipment.)

      71 - Furniture

      72 - Household and Commercial Furnishings and Appliances

      74 - Office Machines and Visible Record Equipment

      77 - Musical Instruments, Phonographs, and Home-type Radios

      78 - Recreational and Athletic Equipment

When equipment in these Federal Supply Groups is requested by the Contractor and
determined essential by the contracting Officer, the Government will endeavor to
fulfill the requirement with equipment available from its excess personal
property sources, provided the request is made under a cost-reimbursement
contract. Extensions or renewals of approved existing leases or rentals for
equipment in these Federal Supply Groups are excluded from the provisions of
this article.

NIH(RC)-7(4/1/84)                                                   ATTACHMENT 4
OMB Bulletin 81-16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00045-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00045-of-00352.parquet"}]]